



35th international symposium on ALS/MND

6-8 December 2024
Montreal, Canada



Hosts: ALS Society of Canada and ALS Society of Quebec

Organised by the Motor Neurone Disease Association in co-operation with
the International Alliance of ALS/MND Associations

Venue: Palais des Congres de Montreal, Canada

PROGRAMME

35th international symposium on ALS/MND



Organiser of the Symposium



Motor Neurone Disease Association

Francis Crick House
6 Summerhouse Road
Moulton Park, Northampton NN3 6BJ
Tel: +44 1604 250505
Email: symposium@mndassociation.org
www.symposium.mndassociation.org

Held in co-operation with



INTERNATIONAL ALLIANCE
OF ALS/MND ASSOCIATIONS

Venue Address

Palais des Congrès de Montreal
5th Floor, Montreal Convention
Centre, 1001 Pl. Jean-Paul-Riopelle,
Montreal, Quebec H2Z 1H5, Canada

Hosts for the Symposium



ALS Society of Canada

180 Bloor Street West
Suite 500, Toronto
ON M5S 2V6, Canada
Tel: +1 416 497 2267
Email: research@als.ca
www.als.ca



ALS Society of Quebec

5415 Pare, Suite 200
Mount-Royal,
QC H4P 1P7, Canada
Tel: +1 514 725 2653
Email: info@sla-quebec.ca
www.als-quebec.ca

CPD/CME Accreditation

The 35th International Symposium on ALS/MND has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 18 category 1 (external) CPD credits

Ethical MedTech Compliance Approval



The 35th International Symposium on ALS/MND has been approved as COMPLIANT by the Ethical MedTech Conference Vetting Service (CVS).

Welcome

Welcome to Montreal/Bienvenue à Montréal!

On behalf of the ALS Society of Canada and the ALS Society of Quebec, we are pleased to have you join us for the 35th International Symposium on ALS/MND. Each year the Symposium provides an opportunity to bring together the ALS community, researchers, clinicians, health professionals, and ALS/MND associations. The Symposium, in addition to the International Alliance of ALS/MND Association's Annual Meeting and Allied Professionals Forum, unites stakeholders from across the global ALS ecosystem to address the issues facing people affected by ALS today and to contribute to the foundation for a future without ALS/MND.

In Canada more than 4,000 people are living with ALS. Approximately 1,000 people lose their lives to this devastating disease here each year and 1,000 people are newly diagnosed. On a global scale we know the population of people affected by ALS is growing. With that, the network of people we support around each person diagnosed results in a multiplier of at least six – this includes people such as caregivers, family members, and healthcare teams. An increase in the number of people impacted by ALS brings with it a deep sense of urgency to continue our collaborative efforts world-wide in information sharing.

ALS Canada and ALS Quebec continue to work together, alongside each of you, to increase public awareness of the disease and the urgent need to improve care, enhance quality of life, advocate for and empower people living with ALS to make informed decisions, accelerate access to clinical trials, and invest in critical research. A world free of ALS/MND won't come from one single discovery made in one country. It won't be one single person doing the work: it will take all of us to make a global impact.

This year's program looks to inspire and help us better understand ALS/MND and how we can support people living with ALS. We hope you leave the Symposium energized and with a renewed sense of collective action as each of you return home to share your learnings.

Montreal is a city rich in culture. Considered a UNESCO City of Design, we hope you can take some time to explore the streets of Old Montreal and experience the diversity our country has to offer. Montreal's motto is Concordia Salus meaning well-being through harmony: may each of you bring that global sentiment of harmony and unity back to your work in ALS/MND as we collectively take action toward a world free of ALS/MND.

Tammy Moore

CEO

ALS Society of Canada

Claudine Cook

Executive Director

ALS Society of Quebec

Foreword

Welcome to the 35th International Symposium on ALS/MND. For the third time, the symposium is taking place in Canada. Following successful meetings in Vancouver (the 10th symposium in 1999) and Toronto (the 18th symposium in 2007), this is the first time it will be held in Montreal. I am sure you will enjoy exploring all this wonderful city has to offer.

Canada is home to some of the most spectacular and beautiful scenery in the world, as well as 'interesting' weather. If you are feeling the cold this week, you can perhaps comfort yourself knowing that it is not as severe as at 7am on 10 January, 1859, when Montreal registered -42 °C (-44 °F). Canadian scientists and inventors are responsible for many findings relevant to the world of medicine and neuroscience, including the discovery of insulin, confirmed to be an effective treatment by injection into a 14-year-old boy who dramatically improved. This story illustrates that once the mechanism of an illness is understood, effective treatment becomes possible, and perhaps that n-of-1 trials also have their place. In ALS/MND, we are slowly but surely moving in the direction of greater understanding, and particularly for genetic therapies, beginning to make good progress in developing effective treatments. Montreal also hosts the Montreal Neurological Institute, which pioneered work in brain surgery and mapping brain functions, and is the home of Hebbian theory: "neurons that fire together wire together", fundamental for our understanding of neural plasticity and repair.

Although it may not be apparent to visitors, Montreal is, in fact, an island, formed by the confluence of the St Lawrence and Ottawa rivers. I see this as a fitting analogy to our efforts in ALS/MND, where the research we do and the treatments we develop are at the confluence of discovery science and clinical medicine, the two cornerstones on which this Symposium is built. Our themes this year include the staples of genomics, cell biology, disease markers, therapeutic trials and clinical care, and they are augmented by sessions on laboratory models, heterogeneity, neuroinflammation, and the role of RNA both in understanding ALS/MND and as an avenue for developing treatments. We are making strong progress in all these areas, helped by coordinated collaboration across the world. The symposium brings us energy, vision and hope, driving us in our clinics and laboratories over the next 12 months.

I wish you a wonderful, enjoyable and educational meeting.

Ammar Al-Chalabi

Programme Committee Chair

SESSION 1

JOINT OPENING SESSION

Location: 517d

Chairs: A Al-Chalabi (UK) and B Dickie (UK)

08.30 – 08.35

Welcome

A Al-Chalabi (UK) and B Dickie (UK)

08.35 – 08.45

Welcome from the Host Association

08.45 – 09.25

Stephen Hawking Memorial Lecture:

C1 Distinguishing Myth and Reality in Biomedical Research

T Caulfield (Canada)



09.25 – 09.35

International Alliance Forbes Norris Award

09.35 – 09.50

IPG Award and winner's research presentation


09.50 – 10.00

Longitude Prize announcement

10.00 – 10.30

REFRESHMENTS, NETWORKING AND EXHIBITORS

Location: 517 Foyer



SESSION 2A

GENETICS

Location: 520

*Chairs: J Cooper-Knock (UK)
and M Harms (USA)*



10.30 – 11.00

C2 Genetics and phenotypic heterogeneity of ALS/MND in Africa and people of African ancestry

*J Heckmann (South Africa) /
D Singh Sokhi (Kenya)*

11.00 – 11.15

C3 IBD methods detecting distant relatedness between ALS patients facilitate new pathogenic gene discovery

D van Oosten (Netherlands)

11.15 – 11.30

C4 Leveraging identity-by-descent to build pedigrees for disease gene discovery

L Henden (Australia)

11.30 – 11.45

C5 Investigating the female protective effect in ALS: Insights from TARDBP mutations carriers in Italy

M Grassano (Italy)

11.45 – 12.00

C6 Insights into oligogenic inheritance in familial ALS through Whole Genome Sequencing analysis

M Deng (China)

12.00 – 12.15

C7 Exome-wide protein domain burden analysis identifies genetic associations with ALS risk

H Marriott (UK)

12.15 – 12.30

C8 Splitformer identifies intronic splicing variants in ALS

X Tang (China)

12.30 – 12.45

Late Breaking News

C9orf72 expansion creates the unstable folate-sensitive fragile site FRA9A

C Pearson (Canada)

SESSION 2B

IMPROVING CLINICAL MANAGEMENT

Location: 517d

*Chairs: S Feldman (USA) and
C Lunetta (Italy)*

10.30 – 10.50

C9 Dextromethorphan/quinidine (DMQ) in the treatment of bulbar symptoms in ALS: Patient-reported outcomes in a multicenter study

S Spittel (Germany)

10.50 – 11.10

C10 Treatment patterns and survival benefit of edaravone-treated people with ALS in the ALS/MND Natural History Consortium

M Ciepielewska (USA)

11.10 – 11.30

C11 Development of a saliva-suppressing scopolamine patch without side effects

M Ogino (Japan)

11.30 – 11.45

C12 Longitudinal psychometric properties of the DYALS scale in monitoring swallowing function changes in ALS patients

C Cattaneo (Italy)

11.45 – 12.00

C13 Development of optimal screening cut-off values from ALSFRS-R bulbar subscore in detecting different levels of dysphagia in a large cohort of ALS patients

F Cerri (Italy)

12.00 – 12.15

C14 Self-assessment of ALS functional rating scale on the patient's smartphone proves to be non-inferior to clinic data capture

A Maier (Germany)

12.15 – 12.30

C15 Qualitative experiences of Acceptance and Commitment Therapy from the perspectives of people living with MND and therapists: Data from an uncontrolled feasibility study and a randomised controlled trial

R Gould (UK)

SESSION 2C

PRESYMPTOMATIC DETECTION AND EARLY DIAGNOSIS

Location: 524

Chair: M Benatar (USA)

10.30 – 10.45

C16 Pre-symptomatic ALS/FTD: from biology to prevention?

M Benatar (USA)

10.45 – 11.00

C17 Community support information requirements for ALS gene carriers

C Haddad (USA)

11.00 – 11.15

C18 Design of preventative trials in ALS

S Fradette (USA)

11.15 – 11.30

C19 Pre-motor changes in PD: lessons for ALS and FTD

R Postuma (Canada)

11.30 – 11.45

C20 FTD Detection and diagnosis

E Finger (Canada)

11.45 – 12.30

Panel discussion / Q&A

12.30 – 14.00

LUNCH AND NETWORKING

Location: 517a/516

SESSION 3A

GLIA

Location: 520

Chairs: C Henstridge (UK) and
P Pasinelli (USA)

14.00 – 14.15

C21 Are myelinating cells an under-appreciated therapeutic target in ALS?

K Lewis (Australia)

14.15 – 14.30

C22 Interrogating the differential toxicity of C9orf72 astrocytes against ALS motor neurons and FTD cortical neurons

M Myszczyńska (UK)

14.30 – 14.45

C23 Investigation of WDR49 expression in astrocytes as a driver of ALS pathogenesis

M King (UK)

14.45 – 15.00

C24 Targeting RNA binding protein SRSF3 and immune mRNAs translation restores microglia function in ALS

J Kriz (Canada)

15.00 – 15.15

C25 Microglia-dependent synaptic dysregulation and complement activation in C9orf72 ALS iPSC-derived motor neuron-microglia co-cultures

B Vahsen (UK)

15.15 – 15.30

C26 VHB937, a TREM2 stabilizing and activating antibody, strongly reduces pathology after peripheral administration in a broad range of animal models for neuroinflammation and neurodegeneration

D Feuerbach (Switzerland)

SESSION 3B

CLINICAL TRIALS

Location: 517d

Chairs: O Hardiman (Ireland)
and S Paganoni (USA)



14.00 – 14.20

C27 Main results from the ADORE study: An international Phase 3 trial to investigate the efficacy and safety of daily oral edaravone (FNP122) in ALS

L Van den Berg (Netherlands)

14.20 – 14.40

C28 PrimeC, an oral candidate for ALS, demonstrates safety and efficacy in a 12-month Phase 2b trial

M Cudkowicz (USA)

14.40 – 15.00

C29 Safety, tolerability and efficacy of the rho kinase inhibitor fasudil in ALS (ROCK-ALS): A Phase 2, randomise, double-blind, placebo-controlled trial

P Lingor (Germany)

15.00 – 15.15

C30 HERV-K/HML-2 suppression using antiretroviral therapy in ALS

D Pandya (USA)

15.15 – 15.30

C31 Long-term safety and efficacy of ultrahigh-dose methylcobalamin in early-stage ALS: JETALS interim analysis and open-label extended period

R Kaji (Japan)

SESSION 3C

NEUROPHYSIOLOGY

Location: 524

Chairs: B Koritnik (Slovenia) and
M De Carvahlo (Portugal)

14.00 – 14.20

C32 The novel combination of Transcranial Magnetic Stimulation and high-density EMG sensitivity captures ALS decline

A Carobin (UK)

14.20 – 14.40

C33 Long intracortical inhibition is not abnormal in ALS: A threshold tracking TMS study

R McMackin (Ireland)

14.40 – 15.00

C34 Regional cortical gamma band activity reflects motor and cognitive deficits in ALS

M Trubshaw (UK)

15.00 – 15.15

C35 Upper limb somatosensory evoked potentials latency as a biomarker for early-stage ALS

C Lunetta (Italy)

15.15 – 15.30

C36 Peripheral cause for split hand syndrome in ALS: Subclinical involvement of small hand muscles in early affected hands

M de Carvalho (Portugal)

15.30 – 16.00

REFRESHMENTS, NETWORKING AND EXHIBITORS

Location: 517 Foyer

SESSION 4A

IN VITRO MODELS

Location: 520

Chairs: K Talbot (UK) and
H Inoue (Japan)

16.00 – 16.30

C37 ALS-in-a-dish: modelling motor neuron disease using advanced human in vitro models

J Pasterkamp (Netherlands)

16.30 – 16.45

C38 TDP-43 loss of function induces neuromuscular junction degeneration in a human stem cell derived neuromuscular assembloid model

A Salzinger (UK)

16.45 – 17.00

C39 Selective disruption of passive nucleocytoplasmic transport in C9ALS/FTD: Arginine DPRs target FG nucleoporins and disrupt protein movement in a sequence-specific manner

D Solomon (UK)

17.00 – 17.15

C40 C210rf2 mutations point towards primary cilia dysfunction in ALS

P Van Damme (Belgium)

17.15 – 17.30

C41 Embryonic motor neuron programming factors reactivate immature gene expression and suppress ALS pathologies in postnatal motor neurons

E Lowry (USA)

SESSION 4B

EPIDEMIOLOGY

Location: 517d

Chairs: C Ingre (Sweden) and
A Chiò (Italy)

16.00 – 16.15

C42 Association between sleep and ALS-FTSD: A prospective cohort study based on 396,918 UK Biobank participants

T Yang (China)

16.15 – 16.30

C43 A population-based mapping and ecological analysis of ALS incidence in the Republic of Ireland between 1995 and 2022

E Mac Domhnaill (Ireland)

16.30 – 16.45

C44 Association between previous psychiatric disorders and ALS: A population-based prospective cohort study

Y Tan (China)

16.45 – 17.00

C45 Physical activity is associated with lower risk of ALS, including in C9orf72 expansion carriers

J Gao (UK)

17.00 – 17.15

C46 Neighbourhood deprivation and functional impairment in ALS

R Boyle (USA)

17.15 – 17.30

C47 Epigenetic age acceleration is associated with ALS risk, survival, occupational exposures and sex

X Li (USA)



SESSION 4C

MOTOR NEURON HETEROGENEITY

Location: 524

Chairs: M Weber (Switzerland) and
N Leigh (UK)

16.00 – 16.30

C48 Cellular vulnerability and disease spread in amyotrophic lateral sclerosis: Is it time to re- think upper and lower motor neurons?

J Ravits (USA)

16.30 – 17.00

C49 The importance of understanding the biology and pathology of upper motor neurons for building effective treatment strategies

H Ozdinler (USA)

17.00 – 17.15

C50 Network spreading and local biological vulnerability in ALS

A Farahani (Canada)

17.15 – 17.30

C51 Somatic mosaicism in ALS and FTD reveals widespread degeneration from focal mutations

Z Zhou (USA)

POSTER SESSION A

Location: 517b/c

17.30 – 19.00

- Theme 1** Epidemiology and Informatics
- Theme 5** Human Cell Biology and Pathology (including iPSCs)
- Theme 6** Tissue Biomarkers
- Theme 8** Clinical Imaging and Electrophysiology
- Theme 11** Cognitive and Psychological Assessment and Support
- Theme 12** Clinical Management and Support

07.00 – 08.30

INDUSTRY SPONSORED BREAKFAST SESSION (NON-CME)

Location: 518

Breaking Barriers: Using Technology to Reduce Diagnostic Delay in ALS

Faculty: A Genge, Chair (Canada), A Fiander (Canada), C Reyenga (Canada), D Walk (USA)

SESSION 5A

CELL BIOLOGY AND PATHOLOGY



Location: 520

Chairs: J Atkin (Australia) and J Gregory (UK)

08.30 – 09.00

C52 On brains and vessels: How vascular mechanisms contribute to ALS neurodegeneration

S Lewandowski (Sweden)

09.00 – 09.15

C53 Sporadic ALS-TDP does not represent a single homogeneous neuropathology

R Tan (Australia)

09.15 – 09.30

C54 Amygdala iron changes are associated with cognitive performance, behavioural deficit and TDP-43 pathology

H Spence (UK)

09.30 – 09.45

C55 Molecular and cellular mechanisms of cognitive impairment in ALS

C Gouveia Roque (USA)

09.45 – 10.00

C56 Harnessing a key chaperone to halt TDP-43 aggregation in MND

R San Gil (Australia)

SESSION 5B

RESPIRATORY MANAGEMENT

Location: 517d

Chairs: D Berlowitz (Australia) and A Calvo (Italy)

08.30 – 09.00

C57 Optimising non-invasive ventilation in ALS

D McKim (Canada)

09.00 – 09.15

C58 Respiratory measurements, respiratory symptoms and quality of life in ALS: Results from the REVEALS study

D Murray (Ireland)

09.15 – 09.30

C59 Peak Inspiratory Flow (PIF) as a predictor of early respiratory decline in ALS

U Manera (Italy)

09.30 – 09.45

C60 Respiratory quotient as independent predictor of prognosis in a large cohort of ALS patients

F Cerri (Italy)

09.45 – 10.00

C61 Monitoring the progression of hypoventilation for indicating when to use breathing support in patients with ALS/MND

P Cazzolli (USA)

SESSION 5C

NEUROIMAGING

Location: 524

Chairs: S Kalra (Canada) and J Grosskreutz (Germany)

08.30 – 08.45

C62 Cortical and subcortical volumetric MRI biomarkers of C9orf72 repeat expansions

C McMillan (USA)

08.45 – 09.00

C63 Regional vulnerability of the connectome topology in ALS

B Kalkhoven (Netherlands)

09.00 – 09.15

C64 Attrition-corrected cerebral cortical thickness as a longitudinal imaging biomarker in ALS

MJ Wendebourg (Netherlands)

09.15 – 09.30

C65 Individual ALS progression markers and disease sub-trajectories encoded in multimodal neuroimaging data

T Baumeister (Canada)

09.30 – 09.45

C66 Multimodal MRI clustering identifies three distinct neurodegeneration-based subtypes of ALS

P Van Lieshout (Netherlands)

09.45 – 10.00

C67 Stronger together: The effect of cognitive abilities and cortical thickness on speech timing abilities in ALS

J Bradsby (Canada)

10.00 – 10.30

REFRESHMENTS, NETWORKING AND EXHIBITORS

Location: 517 Foyer

SESSION 6A

PROTEOSTASIS AND PROTEOTOXICITY

Location: 520

*Chairs: H Durham (Canada) and
B Turner (Australia)*

10.30 – 11.00

C68 Transmission of Misfolded Proteins in Neurodegenerative Disorders: A Common Mechanism of Disease Progression

V Lee (USA)

11.00 – 11.15

C69 Structures of pathological TDP-43 filaments in ALS and FTD

D Arseni (UK)

11.15 – 11.30

C70 A stress-dependent TDP-43 SUMOylation program preserves neuronal function

T Suk (Canada)

11.30 – 11.45

C71 LRSAM1 mitigates neurodegeneration in ALS by regulating clearance of TDP-43

T Shirakawa (USA)

11.45 – 12.00

C72 Pre-symptomatic pathological TDP-43 aggregation is a common feature in peripheral, non-central nervous system tissues in people with ALS

J Gregory (UK)

12.00 – 12.15

C73 Intrinsic and TDP-43 dysfunction-driven cellular degradation loads evoke Tfe3a-associated neuroprotective autophagy in large spinal motor neurons

K Asakawa (Japan)

12.15 – 12.30

C74 Enhancing proteostasis in ALS through novel brain-penetrating peptides: A therapeutic approach targeting autophagy

A Amin (Australia)

SESSION 6B

EXPERIMENTAL MEDICINE AND TRIAL DESIGN



Location: 517d

*Chairs: A Genge (Canada) and
P van Damme (Belgium)*

10.30 – 11.10

C75 Experimental Medicine to identify therapies in ALS

M Turner (UK)

11.10 – 11.30

C76 Evaluating and optimizing an ALS platform trial design: Insights for future directions

L Chibnik (USA)

11.30 – 11.45

C77 Boosting clinical trial power in ALS with AI-generated digital twins

C Kusiak (USA)

11.45 – 12.00

C78 Cultivating patient preferences in ALS clinical trials: The Patient- Ranked Order of Function (PROOF)

R van Eijk (Netherlands)

12.00 – 12.15

C79 Longitudinal comparison of the Italian version of the ALSFRS- R and ROADS: An Italian multicenter prospective study

E Matteoni (Italy)

12.15 – 12.30

C80 Harmonization e-learning for ALS clinical trials: ALSFRS-R harmonized online training platform for cross-continent collaboration

G Kittle (USA)

SESSION 6C

COGNITIVE AND BEHAVIOURAL CHANGE

Location: 524

*Chairs: E Mioshi (UK) and
S Abrahams (UK)*

10.30 – 11.00

C81 Defining concepts and modifiers of cognition in ALS

C McMillan (USA)

11.00 – 11.15

C82 Age-related incidence of neurodegenerative diseases in C9orf72 expansion carriers from a population-based cohort

J Gao (UK)

11.15 – 11.30

C83 The features of behavioural impairment in Chinese ALS patients

J Tang (China)

11.30 – 11.45

C84 Cognitive screening in ALS in Ireland: A 10-year study of prevalence, instrument sensitivity and confounding factors

E Costello (Ireland)

11.45 – 12.00

C85 Predicting cognitive and behavioural decline in ALS patients: a prospective pilot study

A Chio (Italy)

12.00 – 12.15

C86 Development of cognitive/ behavioural disturbances in motor neuron diseases: Can we predict it?

P Ferraro (Italy)

12.15 – 12.30

C87 Prodromal mild cognitive impairment in ALS and FTD: A revised framework

C McHutchison (UK)

12.30 – 14.00

LUNCH AND NETWORKING

Location: 517a/516

SESSION 7A

IMMUNITY AND NEUROINFLAMMATION

Location: 520

Chairs: A Malaspina (UK) and
S Boillee (France)

14.00 – 14.20

C88 RIG-1 but not Sting mediate neuron specific IFN type 1 signalling in FUS-ALS induced neurodegeneration and offers new biomarker driven individualized treatment options

A Herman (Germany)

14.20 – 14.40

C89 Investigating the metabolic crosstalk between senescent T cells and microglia from patients with ALS

V Tsang (UK)

14.40 – 15.00

C90 Functionally distinct Treg subsets exhibit unique mechanisms of dysfunction in ALS

C Baecher-Allan (USA)

15.00 – 15.15

C91 Immune checkpoint changes correlate with the progression and prognosis of ALS

S Chen (China)

15.15 – 15.30

C92 Longitudinal analysis of T cell responses in ALS

S Yazdani (Sweden)

SESSION 7B

AUTONOMY AND DECISION MAKING

Location: 517d

Chairs: D Lule (Germany) and
C Lomen-Hoerth (USA)

14.00 – 14.45

C93 MAID: From legislation to practice

W Johnston (Canada)

14.45 – 15.00

C94 The OCEAAMM: A decision support tool to evaluate competency to consent to MAID

S Charbonneau (Canada)

15.00 – 15.15

C95 The use of support strategies to improve mental capacity to make treatment decisions in ALS

S Abrahams (UK)

15.15 – 15.30

C96 SOD1 gene screening in ALS: Frequency of mutations, patients' attitudes to genetic information and translation to tofersen treatment in a multi-center program

T Meyer (Germany)

SESSION 7C

ANTISENSE AND siRNA-BASED THERAPEUTIC STRATEGIES



Location: 524

Chairs: T Miller (USA) and
C Shaw (UK)

14.00 – 14.30

C97 Antisense-based therapies for rare neurological diseases

F Bennett (USA)

14.30 – 14.45

C98 Update on Silence ALS: A platform for the discovery and development of antisense therapeutics for patients with ultra-rare forms of ALS

N Shneider (USA)

14.45 – 15.00

C99 Antisense oligonucleotides are broadly distributed but do not provide sustained suppression of G4C2 pathology in c9ALS patients

J Glass (USA)

15.00 – 15.15

C100 Deep learning modeling of rare noncoding genetic variants in human motor neurons defines CCDC146 as a therapeutic target for ALS

T Moll (UK)

15.15 – 15.30

C101 Development of an UNC13A cryptic exon skipping antisense oligonucleotide as a treatment for ALS

M van der Brug (USA)

15.30 – 16.00

REFRESHMENTS, NETWORKING AND EXHIBITORS

Location: 517 Foyer

SESSION 8A

RNA BIOLOGY

Location: 520

Chairs: J Robertson (Canada)
and B Rojelj (Slovenia)



16.00 – 16.30

C102 Using spatial genomics to study the central nervous system in health and disease

H Phatnani (USA)

16.30 – 16.45

C103 Employing advanced long-read RNA sequencing in post mortem brain specimens to explore transcriptomic diversity associated with upper and lower motor neuron pathology

A Jain (USA)

16.45 – 17.00

C104 Single-nucleus transcriptome atlas of orbitofrontal cortex in ALS and FTLN with a deep learning-based decoding of alternative polyadenylation mechanisms

P McKeever (Canada)

17.00 – 17.15

C105 Exploring ALS differential vulnerability using single-cell transcriptomic analysis

P Alipour (Canada)

17.15 – 17.30

C106 A journey through space and time: ALS human and mouse spinal cords demonstrate altered gene expression relative to disease pathology

S Howe (Australia)

SESSION 8B

BIOMARKERS

Location: 517d

Chairs: P Corcia (France) and
A Thompson (UK)

16.00 – 16.20

C107 Elevated cerebrospinal fluid UCHL1 in asymptomatic C9orf72 hexanucleotide repeat expansion carriers

E Dellar (UK)

16.20 – 16.40

C108 Combination of serum neurofilament light and serum cardiac troponin T improves diagnostic accuracy in ALS

P Weydt (Germany)

16.40 – 17.00

C109 Total tau and phosphorylated tau levels as diagnostic biomarkers for ALS

T Petrozziello (USA)

17.00 – 17.20

C110 Development of a blood test to distinguish amyotrophic lateral sclerosis from primary lateral sclerosis

S Banack (USA)

POSTER SESSION B

Location: 517b/c

17.30 – 19.00

Theme 2 Genetics and Genomics

Theme 3 *In vitro* Experimental Models

Theme 4 *In vivo* Experimental models

Theme 7 Pre-clinical therapeutic strategies

Theme 9 Clinical Trials and Trial Design

Theme 10 Disease Stratification and Phenotyping of Patients

Work in Progress – Biomedical/Care Practice

POSTER SESSION C

Location: 517b/c

8.30 – 10.00

Open Session

10.00 – 10.30

REFRESHMENTS, NETWORKING AND EXHIBITORS

Location: 517 Foyer



SESSION 9A

MURINE MODELS

Location: 520

Chairs: C Blizzard (Australia) and
J-P Julien (Canada)

10.30 – 10.50

C111 A TBK1 variant causes autophagolysosomal and motoneuron pathology without neuroinflammation in mice

D Brenner (Germany)

10.50 – 11.10

C112 Developing an inducible muscle-specific TDP-43 mouse model to investigate ALS

A Russell (Australia)

11.10 – 11.30

C113 TDP-43 cytoplasmic mislocalisation drives synaptic dysfunction and persistent non-motor behavioural changes in the rNLS8 mouse model of ALS/FTD

W Luan (Australia)

11.30 – 11.45

C114 Spatial transcriptomic profiling of the lower motor neuron circuitry reveals an axonal-specific RNA signature and local translation defects in mutant FUS-mediated ALS

D Piol (Belgium)

11.45 – 12.00

C115 Unveiling a novel mechanistic link between oxidative stress and pathophysiology of Amyotrophic Lateral Sclerosis

E Eftekharpour (Canada)

12.00 – 12.15

C116 Comparison of the motor neuron transcriptome in mouse models of ALS and SMA reveals defects specific to protein translation

H Smith (UK)

12.15 – 12.30

C117 Assessing in vivo axonal transport of mitochondria and signalling endosomes in distinct α -motor neuron subtypes in SOD1G93A mice

A Tosolini (Australia)

SESSION 9B

INTERDISCIPLINARY CARE: POLICY AND PRACTICE

Location: 517d

Chairs: M Ogino (Japan) and
J Bedford (UK)

10.30 – 10.50

C118 Clinicians' Perceptions of Palliative Care for Amyotrophic Lateral Sclerosis (ALS): Results of National Surveys of Interdisciplinary ALS and Palliative Care Clinicians in the United States

K Bischoff (USA)

10.50 – 11.10

C119 How do multidisciplinary teams support people with MND to make decisions about gastrostomy placement: a qualitative multiple case study

S White (UK)

11.10 – 11.30

C120 How do people living with MND and their carers experience specialized care? Development and validation of a patient reported questionnaire

AK Schmidt (Netherlands)

11.30 – 11.50

C121 Virtual care delivery models and team functioning in ALS – a pan-Canadian experience with interdisciplinary virtual care in ALS

B Ritsma (Canada)

11.50 – 12.10

C122 Proposal for a U.S National Integrated ALS Care and Research Network System- Excerpts from the National Academies of Medicine Report on ALS

S Babu (USA)

12.10 – 12.30

C123 The EU ALS Coalition call for action: Roadmap of the policy changes needed across Europe to improve the lives of PLWALS and their carers across Europe

J Grosskreutz (Germany)

SESSION 9C

BIOMARKERS (II)

Location: 524

Chairs: R Bowser (USA) and
M Hafezparast (UK)



10.30 – 10.50

C124 Novel prognostic protein discovery using Olink proximity extension assay in a large longitudinal ALS cohort

D Lester (UK)

10.50 – 11.10

C125 Detection and Discovery of Urinary Biomarkers of Immune Dysfunction for Amyotrophic Lateral Sclerosis

V Karnaros (Australia)

11.10 – 11.30

C126 Targeted proteomics upon Tofersen treatment highlights candidate therapy-responsive markers for SOD1-linked ALS

A Catanese (Germany)

11.30 – 11.50

C127 Longitudinal analysis of immune cell changes in FUS- ALS patients treated with a FUS antisense oligonucleotide

O Rifai (USA)

11.50 – 12.10

C128 Corneal small fiber neuropathy in ALS patients: a corneal confocal microscopy study

Z Zou (China)

12.10 – 12.30

C129 Seed-amplification assays: Windows into ALS and kindred diseases

R Smith (USA)

12.30 – 14.00

LUNCH AND NETWORKING

Location: 517a/516

SESSION 10

JOINT CLOSING SESSION

Location: 517d

Chairs: A Al-Chalabi (UK) and K Dave (USA)

13.30 – 13.40

Invitation to San Diego 2025

13.40 – 13.50

Poster Prize Awards

13.50 – 14.00

Healey Prize

14.00 – 14.10

Lalji Family Award

14.10 – 14.30

C130 Early onset sleep alterations in ALS and their mechanisms

L Dupuis (France)

14.30 – 15.00

C131 Outcome measures in ALS clinical trials: progress to date and future directions

A Genge (Canada)

15.00 – 15.10

Late breaking news

A clinical trial transplanting CNS10-NPC-GDNF into the motor cortex of ALS patients: Survival, migration and differentiation into non-reactive GDNF-secreting GLAST-positive astrocytes

C Svendsen (USA)



THEME 01

Epidemiology and Informatics

EPI-01 Target ALS Natural History Study in a Global ALS Population

Ms Laura Dugom

EPI-02 Estimated prevalence of als in the republic of kazakhstan

Ms Aruzhan Asanova

EPI-03 Epidemiology of ALS in a Tertiary Center from Northeast Brazil (from 2013 to 2023)

Professor Francisco de Assis Aquino Gondim

EPI-04 Methodological considerations in the analysis of survival data in amyotrophic lateral sclerosis

Dr Solmaz Yazdani

EPI-05 Place of death surrounding Motor Neuron Disease Mortality in the United States before and during the COVID-19 Pandemic, 2018-2021

Mrs Jaime Raymond

EPI-06 Head injury and amyotrophic lateral sclerosis: population-based study from the National ALS Registry

Mrs Jaime Raymond

EPI-07 Body Composition affects the Occurrence of Amyotrophic Lateral Sclerosis in Sex- and Age-Dependent manners

Miss Jiajia Fu

EPI-08 The sex-specific effect of apolipoprotein E ϵ 4 E and lipids on onset and prognosis of amyotrophic lateral sclerosis

Dr Jiajia Fu

EPI-09 Apolipoproteins, lipids, lipid-lowering drugs and risk of ALS or FTD

Dr Christos Chalisios

EPI-10 Relationship between prior exposure to arthropod-borne viruses and amyotrophic lateral sclerosis

Dr Nortina Shahrizaila

EPI-11 Occupational lead exposure in a pre-symptomatic familial ALS cohort

Dr Johnathan Cooper-Knock

EPI-12 Assessment of urbanization, air pollution and water pollution as environmental risk factors of amyotrophic lateral sclerosis: A matched-case control study

Mr Daniel Saucier

EPI-13 Racial disparities in the diagnosis and prognosis of ALS patients in the United States

Dr Paul Mehta MD

EPI-14 Area deprivation is associated with survival, severity of impairment, and time from onset in ALS

Dr Nimish Thakore

EPI-15 Valuing interpersonal carer-patient relationships attenuates the carer QALY trap in ALS

Dr Nimish Thakore

EPI-16 POSTER WITHDRAWN

EPI-17 Transition in Amyotrophic Lateral Sclerosis (ALS) Home Mechanical Ventilation (HMV) in Japan: Changes Over the Past 50 Years

Ms Yuki Nakayama

EPI-18 Evidence Requirements for Establishing Diagnosis of Amyotrophic Lateral Sclerosis in Historical Medical and Non-Medical Sources: 'Endemic Paraplegia of Koza in Kii' Published in 1689 Honcho Koji Innen Shu Reported by Yoshino Yase

Professor Benjamin Rix Brooks

EPI-19 The Canadian Neuromuscular Disease Registry: using real-world evidence to further ALS research in Canada

Dr Gordon Jewett

EPI-20 Clinical and Genetic Characteristics of 1672 Cases of Amyotrophic Lateral Sclerosis in China: A Single-Center Retrospective Study

Dr Mingsheng Liu

EPI-21 Clinical and genetic characterization of SOD1 mutations in a Taiwanese cohort with amyotrophic lateral sclerosis

Mr Shih-yu Fang

EPI-22 A Scalable Platform and Models for Decentralized Observational and Validation of Digital Biomarkers Studies in People Living with ALS/MND

Mr Alexander Sherman

THEME 02

Genetics and Genomics

GEN-01 The Genetics of Motor Neuron Disease in New Zealand

Mr Miran Mrkela

GEN-02 Updated clinical and genetic characteristics of juvenile amyotrophic lateral sclerosis in China: a single-center retrospective study

Professor Xunzhe Yang

GEN-03 Genetic modifier of age at onset in Japanese patients with amyotrophic lateral sclerosis

Dr Ryoichi Nakamura

GEN-04 'VUS SOS' The Variant of Uncertain Significance Second Opinion Service

Professor Matthew Harms

GEN-05 In Depth study of ALS Loci by Genome-wide analysis

Miss Xuelin Tang

GEN-06 Towards a multiomic atlas of the motor cortex and lumbar spinal cord in health and ALS

Ms Natalie Barretto

GEN-07 Localized molecular chaperone synthesis maintains neuronal dendrite proteostasis

Dr Celia Alecki

GEN-08 Assessment of variable disease penetrance in familial and sporadic ALS

Dr Andrew Douglas

GEN-09 Family communication of genetic test results for Amyotrophic Lateral Sclerosis

Ms Emily Spoth

GEN-10 Family-based Gene Discoveries in ALS: Comprehensive literature review and analysis of Dutch FALS cohort

Ms Bi-nan Wang

GEN-11 Ethical dilemmas in ALS predictive testing for monozygotic twins: Clinical case report

Ms Miranda Li

GEN-12 Genetic Counseling and Testing Educational Resources: A Call to Action from the Genetic Summit Hosted by the International Alliance of ALS/MND Associations

Ms Lauren Webb

GEN-13 Four Families with p.Val120Leu (c.358G > C) SOD1 mutations and Slowly Progressive ALS in Northeast Brazil (State of Ceará)

Professor Francisco de Assis Aquino Gondim

GEN-14 Clinical Decision Making Over SOD1 Uncertainty

Ms Tara Jones

GEN-15 FUS-mediated gene expression links genetic risk to selective neuronal degeneration in ALS

Dr Luc Dupuis

GEN-16 Targeted long-read sequencing of C9orf72 hexanucleotide repeat expansion in a longitudinal cohort

Dr Beatrix Cardus

GEN-17 Somatic mutations in single neurons from C9ORF72 amyotrophic lateral sclerosis and frontotemporal dementia brains

Dr Zinan Zhou

GEN-18 Quantifying methylation of the C9orf72 repeat expansion in multiple human tissues

Mr Evan Udine

GEN-19 Increased cofilin activity rescues neuronal phenotypes in C9orf72 knockout mice

Ms Lauren Joe

GEN-20 Repeat Instability, Chromosomal Fragility, Chromosomal Instability in C9orf72 Expansion

Dr Katsuyuki Yokoi

GEN-21 Investigating the Oligogenic Model of Amyotrophic Lateral Sclerosis

Ms Sarah Gornall

GEN-22 N of 1 trial of Antisense Oligonucleotide for CHCHD10 ALS, initial experience

Dr Björn Oskarsson

GEN-23 Gene editing approaches to pathomechanisms and treatment of CHCHD10-associated ALS

Mrs Adriana Morales Gomez

GEN-24 Distinct founder haplotypes across global CHCHD10 p.Arg15Leu amyotrophic lateral sclerosis patients

Dr Kelly Williams

GEN-25 rs12608932 polymorphism in UNC13A as a risk factor in a cohort of Spanish patients with ALS

Dr. Alberto García Redondo

GEN-26 The Impact of CYP2D6 Variations on Survival in Amyotrophic Lateral Sclerosis: A Pharmacogenetic Analysis

Miss Johanna Kristiina Jaansoo

GEN-27 The clinical and genetic landscape of UBQLN2-linked ALS/FTD; a meta-analysis of variant pathogenicity and sex differences

Miss Kyrah Thumbadoo

GEN-28 Mutation screening of ATXN1, ATXN2, and ATXN3 in ALS

Dr Tianmi Yang

GEN-29 TNFSF13 as a potential drug target for ALS: A proteome-wide Mendelian randomisation analysis

Dr Christos Chalitsios

GEN-30 The priority index pipeline recapitulates known ALS biological pathways and suggests novel drug targets

Dr Harpreet Saini

GEN-31 The New York Genome Center ALS Consortium combines postmortem tissue transcriptomics with whole genome sequencing to empower biological discovery

Dr Jack Humphrey

GEN-32 Project MinE: new whole genome sequencing data freeze for rare genetic variant discovery in ALS

Miss Fabienne Kick

THEME 03

In vitro Experimental Models

IVT-01 GRASPS: a novel translome technology reveals omics-hidden disease-associated pathways in TDP-43-related ALS

Dr Ya Hui Lin

IVT-02 Protein mimetic antagonists of TDP-43 aggregation mitigate cytotoxic phenotypes in multiple ALS models

Mr Kevin Reynolds Caicedo

IVT-03 Overexpression of HSP-27 Reduces TDP-43 Aggregation

Mr Muhammad Abeer

IVT-04 Impact of miRNAs on G3BP1 mRNA stability and their implication in TDP-43 associated amyotrophic lateral sclerosis

Miss Andreanne Lacombe

IVT-05 IκB kinase phosphorylates cytoplasmic TDP-43 and promotes its proteasome degradation

Mr Yohei Iguchi

IVT-06 Rapid and Inducible Mislocalization of Endogenous TDP-43 in a Novel Human Model of Amyotrophic Lateral Sclerosis

Miss Johanna Ganssauge

IVT-07 Characterisation of ALS/FTD-associated RNA-binding deficient mutant TDP-43

Miss Molly Magarotto

IVT-08 Targeting TDP-43 proteinopathy by the combination of colchicine/ metformin: A novel strategy for the treatment of ALS/FTD

Dr JuHo Youn

IVT-09 Blocking TDP-43 SUMOylation impairs recovery from cellular stress

Miss Jenny Zhang

IVT-10 Unraveling TDP-43 Pathology in Oligodendrocytes Using a Novel Stem Cell-Derived Model

Miss Tania Atienzar

IVT-11 Investigating FUS and TDP-43 assemblies in silico to engineer structure-based ALS antigens enabling antibody-based diagnostics

Dr Holger Wille

IVT-12 FUS activity at synapses is modulated through mechanistic target of rapamycin complex 2 (mTORC2)

Mr Bastien Glasson

IVT-13 The Propagation of ALS Pathogenic Protein Misfolded SOD1 Aggregation in hiPSC-derived Cerebral Organoids

Ms Boting Li

IVT-14 In vitro and in vivo network cortical hyperexcitability in the G93A-SOD1 mouse model of Amyotrophic Lateral Sclerosis

Miss Marilina Douloudi

IVT-15 Investigating a potential new mechanism of neuromuscular junction denervation in ALS

Miss Marion Boyer

IVT-16 Towards building a screenable human three-dimensional (3D) neuromuscular junction (NMJ) in vitro model of ALS

Ms Maria Jose Castellanos-Montiel

IVT-17 Generation and characterization of spinal cord organoids for the study of amyotrophic lateral sclerosis

Dr Matteo Bordonì

IVT-18 A human stem cell-derived microfluidic 3D triculture model to study astrocyte, microglia, and motor neuron interactions and neuroinflammation in C9orf72 ALS

Dr Marianne King

IVT-19 Addressing iPSC derived motor neuron variability to improve model reproducibility for Motor Neuron Disease (MND) therapeutic discovery

Mr Finbar Gaffey

IVT-20 Bioinformatic quality control of CRISPR-Cas9 modified iPSC lines in the UK MND Research Institute

Dr Aleksandra Mech

IVT-21 Investigating microglia mediated neuroinflammation in stem cell derived models of c9orf72 amyotrophic lateral sclerosis

Dr Elena Di Daniel

IVT-22 Development of an in vitro 3D ALS model with patient-derived cells

Dr Mathilde Chaineau

IVT-23 Investigating the therapeutic potential of targeting the astrocytic EMMPRIN activation in Amyotrophic Lateral Sclerosis

Dr Silvia Pozzi

IVT-24 Methylglyoxal-induced stress causes senescence and dysregulation of ALS-associated markers

Dr Veronica Noches

THEME 04

In vivo Experimental Models

IVV-01 ERVK integrase-driven DNA damage leads to motor deficits

Dr Renée Douville

IVV-02 Alternative polyadenylation in human ALS is recapitulated in Drosophila models of TDP-43 proteinopathy

Mr Peter Forstmeier

IVV-03 TARDBP (TDP-43) knock-in zebrafish models of the A382T and G348C variants display an ALS-like phenotype that arises from partial loss-of-nuclear function

Mr Ziyaan Harji

IVV-04 TDP-43 SUMOylation safeguards from neurodegeneration in vivo

Miss Veronica Grybas

IVV-05 Viral-mediated Atxn2 reduction mitigates TDP-43 pathology and muscle dysfunction in the PFN1-C71G mouse model of ALS

Dr Deborah Kwon

IVV-06 Neurons with cytoplasmic TDP-43 accumulation develop degradative organelle disruptions

Adam Walker

IVV-07 Chronic hyperthermia in TDP-43 mice correlates impaired stress granule assembly to TDP-43 translocation and motor neuron loss

Ms Mariam Choughari

IVV-08 Proteomic analysis of the TDP-43 associated insoluble fraction from TDP-43 Δ NLS mouse brain suggests sustained stress granule formation, CLUH granule recruitment and impaired mitochondrial metabolism

Professor Aaron Russell

IVV-09 The gut microbiota is a determinant of sexual dimorphism in ALS-linked TDP43 mice

Dr Evandro Beraldi

IVV-10 Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis

Dr Taide Wang

IVV-11 RNA aptamers are capable of rescuing motor neurons and improving motor function in both sporadic and familial mouse models of ALS

Dr Megumi Akamatsu

IVV-12 miR-146a as a pleiotropic regulator of motor neuron degeneration

Dr Dylan Galloway

IVV-13 Arylamine N-acetyltransferase 1 (NAT1) may facilitate muscle responses to MND early and during disease

Ms Melinder K Gill

IVV-14 Efficacy and quality of neuromuscular junction reinnervation: impacts in ALS

Mr Simon Alvado

IVV-15 A murine ex vivo assay to target synaptic dysfunction in motor neuron disease

Dr Alannah Mole

IVV-16 Peripheral nerve injuries can induce focal disease onset in the SOD1 rat model of ALS

Miss Haley Cropper

IVV-17 Intracisternal Injection of SOD1 Aggregates Induces ALS Disease in Transgenic Mouse Models

Ms Isabelle Sigfridsson

IVV-18 Demetalation not monomerization of mutant SOD1G93A correlates with pathology in SOD1G93A transgenic mice

Mr Tyler Wells

IVV-19 Superoxide Dismutase 1 G93A increases the response of macrophages to produce inflammatory factors that could contribute to development of Amyotrophic Lateral Sclerosis

Dr Gary Pattee

IVV-20 Targeting neuregulin to slow disease progression in ALS

Professor Fei Song

IVV-21 Targeting SPP1 in ALS neurodegeneration

Dr Sebastian Lewandowski

IVV-22 Neuronal reprogramming to promote longevity and repair in ALS

Dr Hussein Ghazale

IVV-23 Astrocytic dysfunction caused by FUSR521G promotes NF- κ B activation and ALS-associated phenotypes

Mrs Mari Carmen Pelaez

IVV-24 Characterization of a humanized FUS mouse model expressing the ALS-linked mutation P525L

Dr Graciana De Azambuja

IVV-25 Examining the spatiotemporal dynamics of disease in a juvenile-onset FUS-ALS mouse model

Ms Olena Kuksenko

IVV-26 The dipeptide-repeat protein Poly-AP causes age-dependent neuronal swellings and perturbations to locomotor rhythmicity in a Drosophila model of C9orf72 MND

Mrs Charlotte Gale-Rogers

IVV-27 Pharmacological and genetic modifiers of ALS-associated phenotypes in Drosophila melanogaster and patient-derived cells

Dr Hrvoje Augustin

IVV-28 Development of a Dipeptide Repeat Protein (DPR) Challenge Assay in Larval Zebrafish for Screening Protective Compounds

Ms Val Tassinari

IVV-29 Investigating the link between cerebellar pathology and the loss of c9orf72 function in a zebrafish ALS model

Mr Jaskaran Singh

IVV-30 Cell-type and region-specific transcriptomic and epigenomic disturbances resulting from C9orf72 reduction in the murine frontal cortex and hippocampus

Dr Paul McKeever

IVV-31 C9ORF72 Deficiency Results in Neurodegeneration in the Zebrafish Retina

Dr Marcus Keatinge

IVV-32 Deconstructing the roles of oligodendrocytes and neurons in mediating TDP43-related MND neurodegeneration

Dr Marcus Keatinge

IVV-33 Calpastatin: A potential therapeutic target in C9orf72 ALS to preserve motor neuron degeneration

Dr Léa Lescouzères

IVV-34 Lithium inhibition of GSK3 β alters the expression of pThr231 tau and calcium-regulating proteins Calb-1 and MCU in a rodent model of traumatic brain injury

Ms Jacqueline Palik

IVV-35 C9orf72 loss enhances glutamate-mediated excitotoxicity

Mr Belay Gebregergis

IVV-36 Edaravone reduces the enhanced glutamatergic transmission onto motor neurons in the spinal cord of a mouse model of amyotrophic lateral sclerosis

Dr Yun Kyung Park

IVV-37 Expanded characterization and validation of the Prp-hPFN1G118V mouse model for preclinical drug testing

Ms Kaly Mueller

IVV-38 Splicing and Transcriptomic changes in Matrin 3 S85C Knock-in Mice

Dr David Medina

IVV-39 Probiotics as Therapeutics for Neurodegeneration

Professor Alex Parker

IVV-40 Therapeutic Potential of Cannabis-Derived Formulations in Mitigating Motor Neuron Disease

Mr Akeem Gardner

THEME 05

Human Cell Biology and Pathology (including iPSC studies)

HCB-01 C-BIG: An Open Science Bio-Repository and Patient Registry (Clinical, Biospecimen, Imaging and Genetics) - A Multi-Modal, Integrated Approach to Biobanking

Mrs Marie-Noëlle Boivin

HCB-02 Brain Bank for Aging Research-recommended neuropathology protocol for amyotrophic lateral sclerosis (ALS)

Professor Shigeo Murayama

HCB-03 Investigating Cellular Profiling in ALS through the Application of Geneformer, a Large-scale Language Model on scRNA-seq Data Analysis

Mr Yuki Shiiba

HCB-04 Investigating the pathogenic role of aberrant intron retention in amyotrophic lateral sclerosis

Dr Yiran Wang

HCB-05 Investigating the role of cryptic G3BP1 in ALS neuropathogenesis

Dr Hana Fakim

HCB-06 Brain Barriers Breakdown in ALS and ALS-FTD

Dr Nadine Bakkar

HCB-07 Oral treatment with fasudil diminishes the capacity of ALS patient-derived exosomes to induce TDP-43 neuropathology in vitro

Mr Kevin Reynolds Caicedo

HCB-08 Inhibiting glycogen synthase kinase 3 suppresses TDP-43-mediated neurotoxicity in a caspase-dependant manner

Mr Leon Crowley

HCB-09 Understanding the relationship between lipids and TDP-43 aggregation

Miss Tatiana Langerová

HCB-10 Occult TDP-43 pathology in a novel at-risk cohort of individuals with altered bowel habit

Miss Tatiana Langerová

HCB-11 HnRNPD – an understudied subfamily affected in sporadic TDP-43 proteinopathies

Dr Rachel Tan

HCB-12 Disruption of nuclear 3' UTR lengthening coincides with TDP43 mislocalization in ALS-related VCP mutant motor neurons during terminal differentiation

Dr Zhi Ming Xu

HCB-13 Novel TDP-43 aptamers identify early aggregation events in C9orf72 mutant human motor neurons

Miss Orjona Stella Taso

HCB-14 Analysis of TDP-43 splicing targets in cytoplasmic and nuclear fractions from C9orf72 iPSC-derived motor neurons

Ms Therese Dane

HCB-15 Endogenous Retroviruses and the association with TDP-43 and neuroinflammation in Amyotrophic Lateral Sclerosis

Dr Megan Dubowsky

HCB-16 Aberrant TMEM106B C-Terminal Fragment Immunoreactivity Is Associated with Loss of Nuclear TDP43 in C9orf72-ALS/FTD

Mr Muzi Du

HCB-17 A nucleocytoplasmic proteomic screen in C9orf72-associated ALS/FTD

Ms Olivia Houghton

HCB-18 Membrane Protein Dysregulation in C9orf72 Mutation-Associated ALS and FTD

Professor Boris Rogelj

HCB-19 Axonal splicing dysregulation in C9orf72-driven amyotrophic lateral sclerosis

Dr Vladimir Zhemkov

HCB-20 Global transcriptional analysis of C9orf72 patient derived iPSC neurons

Ms Aparna Sreeram

HCB-21 Comparison of rnaSEQ signatures between C9ALS and control iPSC derived motor neurons using two differentiation protocols

Dr Alba Sansa Zaragoza

HCB-22 Ageing-dependent phenotypes are exacerbated by optogenetic stimulation in C9ORF72-HRE ALS motor neurons

Dr Lucy Farrimond

HCB-23 Reduced C9orf72 expression and HRE mutations trigger axonal lysosome defects in iPSC-derived motor neurons

Mr Thomas Krzystek

HCB-24 Generation of human induced pluripotent stem cell-based TDP-43 knockout in vitro model for disease modeling

Ms Anushka Bhargava

HCB-25 An organ-chip model of young onset ALS using patient specific iPSCs

Dr Deepti Lall

HCB-26 Production of oligodendrocytes from patient-derived iPSCs to study ALS

Miss Isabella Bienjonetti

HCB-27 Exploring the Cell Biology of Gene-Environment Interactions in ALS using Human iPSCs

Dr Bryony Thorne

HCB-28 ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective in co-culture of human iPSC-derived motor neurons and muscle

Dr Sherif Reda

HCB-29 Mitochondrial fragmentation and proteomic dysregulation in ALS iPSC-motor neurons

Ms Leanne Jiang

HCB-30 The WW domain-containing oxidoreductase worsens mitochondrial dysfunction and oxidative stress in amyotrophic lateral sclerosis

Dr Adel Boudi

HCB-31 POSTER WITHDRAWN

HCB-32 Stress response genes are downregulated during the switch from asymptomatic to symptomatic MND in reprogrammed astrocytes generated from C9orf72-Carriers: Loss of compensation or mechanism of motor neuron toxicity?

Mr Allan C. Shaw

HCB-33 DnaJC7 antagonizes the toxic effects of proteostasis stress

Mr Young Joon Kim

HCB-34 Stress granule disruption by CRISPR/dCas13 system

Dr Akira Yamasaki

HCB-35 Assessing the impact of mutations in ARPP21

Miss Esther Alvarez-Sanchez

HCB-36 POSTER WITHDRAWN

HCB-37 STMN2 degradation is regulated by membrane targeting and tubulin binding

Dr Xiang Deng

HCB-38 Involvement of Peripheral Immune Cells in the Progression of Amyotrophic Lateral Sclerosis

Dr Min Zhang

HCB-39 SOD1 enzymatic activity in CSF of ALS patients

Ms Laura Leykam

HCB-40 Mapping mislocalization as a point of convergence in ALS

Dr Dale Martin

HCB-41 Chaperone mediated autophagy is deficient in ALS motoneurons derived from adipose mesenchymal cells and spinal motoneurons of patients

Professor Salvador Martinez

HCB-42 Activation of polo-like kinase 1 contributes to selective motor neuron vulnerability in familial ALS

Professor Andreas Herman

HCB-43 Sigma-1 receptors localize to C-boutons in lower motor neurons: A neuropathological study of bulbar and limb ALS

Dr. Vivian Ko

HCB-44 Proteomic analysis of corpora amylacea extracted from post-mortem brain of MAiD-end-of-life sporadic ALS patients

Mr Alexandre Paquet

HCB-45 Synaptosome proteomics to identify molecular signatures in dementia spectrum disorders

Dr Lathika Gopalakrishnan

HCB-46 Neuropathological signature of ANXA11-linked ALS

Dr Serey Naidoo

HCB-47 Genotypically distinct interferon response signatures correlate with clinical phenotype and respond to therapeutic targeting in ALS

Dr Valeria Gerbino

HCB-48 Antibody-recognizing residues 188-211 of TMEM106B exhibit immunohistochemical reactivity with the TMEM106B C-terminal fragment

Dr Ruoyi Ishikawa

HCB-49 Generation of Patient-Derived Cortical and Spinal Organoids to Study Pathobiology Associated with ALS

Dr Lachlan Thompson

THEME 06

Tissue Biomarker

BIO-01 Early aggregation and spreading of hSOD1 aggregates in ALS model mice

Ms Caitlin Henne

BIO-02 Parvalbumin and calbindin in the CSF are the promising histopathology-associated biomarkers for sporadic ALS

Dr Shintaro Hayashi

BIO-03 Blood-based immunoassays for TDP-43 identify platelets as a major source of TDP-43 in the blood

Professor Robert Bowser

BIO-04 ERVK integrase within CD14+CD11b+ myeloid cells as an ALS blood biomarker

Mrs Claudia Cortes-Perez

BIO-05 Soluble CTLA4 as a theragnostic biomarker of adaptive immune response in amyotrophic lateral sclerosis

Mrs Kristine Roberts

BIO-06 Effects of Anti-Glycolipid Antibodies on the Long-Term Prognosis of Patients With Amyotrophic Lateral Sclerosis: A Prospective Study

Professor Xueping Chen

BIO-07 Prognostic Value of Serum Cardiac Troponin T Elevations in a Real Life Cohort of ALS Patients

Mr Patrick Weydt

BIO-08 POSTER WITHDRAWN

BIO-09 Development and Optimization of TDP-43 Seed Aggregation Assay as a Diagnostic Tool for ALS and FTD

Dr Ganesh M Mohite

BIO-10 Mislocalization of TDP-43 in brains of ALS and FTD patients

Dr. Alberto García Redondo

BIO-11 TDP-43 pathology is a cross-cutting pathological event that occurs across neurodegenerative diseases and with normal ageing

Dr Jenna Gregory

BIO-12 Examining the novel aspects of DNA damage in ALS and unveiling prospective ALS biomarkers

Mrs Shashi Gautam

BIO-13 Biomarkers of proteostasis impairment in amyotrophic lateral sclerosis

Dr Denis Shevchuk

BIO-14 The myokine FGF21 is a novel ALS biomarker that associates with slower disease progression and mitigates stress-induced cytotoxicity

Dr Mohamed Kazamel

BIO-15 Probing oxidative stress changes in neurodegenerative diseases using metabolomics and histo-CLEM on human post-mortem tissue

Dr Holly Spence

BIO-16 A Translational Assay for Ataxin-2 related Drug Development Products

Dr Anna Ettorre

BIO-17 Pharmacodynamic Evidence of CNS Efficacy With CNM-Au8 from The HEALEY ALS Platform Trial Open-Label Extension

Mr Michael Hotchkin

BIO-18 Reduction of Neurofilament Light (NFL) and Chitinase CHI3L1 Biomarker Levels in ALS with CNM-Au8 Treatment, Results from the HEALEY ALS Platform Trial Regimen C Long-Term Open Label Extension (OLE)

Dr Marjan Sepassi

BIO-19 Neurofilament light chain levels in serum and cerebrospinal fluid correlate with Forced Vital Capacity Decline Pattern scale (FVC-DiP) in ALS patients

Dr Yuko Kobayakawa

BIO-20 Phosphorylated Neurofilament Heavy Chain (pNfH) Content of Patients' Cerebrospinal Fluid Reflects ALS Aggressiveness

Professor Julian Grosskreutz

BIO-21 Extracellular matrix protein at Neuromuscular Junction, Laminin β 2, as potential diagnostic biomarker in ALS

Dr Roberta Piovesana

THEME 07

Pre-clinical Therapeutic Strategies

TST-01 Effective knockdown of ATXN2 following intracerebroventricular administration of AVB-205 construct in BAC-ATXN2-Q72 transgenic mice

Chris E Shaw

TST-02 Inhibiting dipeptide repeat propagation in C9-ALS

Dr S. Can Akerman

TST-03 Anaplastic Lymphoma Kinase (ALK) inhibition mitigates synaptic dysfunction in the context of C9orf72 haploinsufficiency

Mr Bryan Kartono

TST-04 Small molecule TDP-43 oligomer/aggregation inhibitor, WTX-245, corrects transcriptional dysfunction across multiple mRNAs in a neuronal cell model for ALS

Dr Bochang Li

TST-05 Small Molecule Targeting of {IP Protein} prevents and reverses TDP-43 aggregation

Dr Marc Shenouda

TST-06 Development of EKZ-102, a highly selective CNS-penetrant small molecule HDAC6 inhibitor for improved axonal transport, proteostasis and neuronal survival in the treatment of ALS

Dr. Tonya Gilbert

TST-07 Allele-selective knockdown of an ALS-causing variant in UBQLN2

Mr David Gordon

TST-08 Novel oral small molecule targets both gain- and loss-of-function TDP-43 pathology for treatment of ALS

Dr Vidhu Mathur

TST-09 Identification of novel small molecule chaperone activators for neurodegenerative disease treatment

Dr Anita Ho

TST-10 M102, a Combined NRF2 and HSF1 Activator, Attenuates Motor Decline in Two Transgenic Mouse Models of ALS

Dr Amy Keerie

TST-11 Exploring increased phosphoglycerate kinase 1 (PGK1) activity as a potential therapeutic target in MND

Ms Harriet McHale-Owen

TST-12 Harnessing the Neuropeptide Y system as a Neuroprotective Strategy in ALS

Professor Tracey Dickson

TST-13 RNS60, A Novel Therapeutic, Protects Mitochondria and Upper Motor Neurons in TDP-43 Amyotrophic Lateral Sclerosis

Dr Mukesh Gautam

TST-14 Discovery of novel mitochondrial therapeutics for ALS using iPSC-derived motor neurons from C9orf72 ALS patients

Dr Neelam Shahani

TST-15 A ketogenic diet promotes mitochondrial adaptability and restores energy status in ALS-FUS mice

Mr Antoine Desmeules

TST-16 Investigating ASO therapeutic strategies in treating the ALS-causing FUS[R521H] variant using adult zebrafish

Mr. Christian Rampal

TST-17 Development of LTX-002, an ASO for the treatment of ALS

Dr Laura Heckman

TST-18 Role of regulatory T cells in the pathogenesis of ALS

Dr Seiichi Nagano

TST-19 GNK-301 a therapeutic antibody neutralizing HERV-K ENV for precision medicine in sporadic ALS

Dr Hervé Perron

TST-20 An Antibody Targeting TDP-43 oligomers Alleviates Motor Symptoms and Neuropathology in an ALS Mouse Model

Dr Wei Wei Chang

TST-21 Therapeutic effects of full-length antibody against TDP-43 in mouse model of disease induced by infusion of CSF from ALS patients

Ms Amélie Poulin-Brière

TST-22 Intravenous injection of viral vector encoding a scFv antibody targeting TDP-43 prevented pathology and symptom phenotypes in three mouse models of ALS and dementia

Dr Jean-pierre Julien

TST-23 Intravenous Delivery of AAV Gene Therapy for the Treatment of SOD1-ALS Provides Broad SOD1 Lowering in NHP

Dr Michael Grannan

TST-24 Effective SOD1 targeting with vMiX™, an innovative AAV-based RNA interference platform

John Isaac

TST-25 Dorsal root ganglion toxicity in nonhuman primates and mice following intra-CSF delivery of an AAV-based artificial microRNA targeting SOD1

Dr Zachary Hawley

TST-26 Developing targeted degradation therapies for SOD1-amyotrophic lateral sclerosis

Miss Caitlin O'Shea

TST-27 Cracking the intrabody problem for ALS

Dr Gareth SA Wright

TST-28 The role of the CXCR4/CXCL12 axis in neuroinflammation and its potential as a therapeutic target for amyotrophic lateral sclerosis treatment

Professor Beka Solomon

TST-29 The novel combination of 2 clinical-stage molecules demonstrates a beneficial effect in preclinical models of ALS

Ms Kim Staats

TST-30 Therapeutic Potential of Systemically Delivered Human Immature Dental Pulp Stem Cells in a Murine Model of Amyotrophic Lateral Sclerosis: A Preclinical Study

Dr Marcondes Cavalcante França-Jr

TST-31 Therapeutic effects of human dental pulp stem cell derived exosomes in transgenic mice SOD1G93A

Mr João Pedro Nunes Gonçalves

TST-32 Global proteomic and phosphoproteomic biomarker profiling of a trifunctional boron-based pyrazole (an Edaravone analog) that increases survival, delays disease onset, and prevents weight loss in a hSOD1 model of Amyotrophic Lateral Sclerosis

Mr Nitesh Sanghai

TST-33 A trifunctional boron-based pyrazole (an Edaravone analog) increases survival, delays disease onset, and prevents ALS-induced cachexia in a hSOD1 model of Amyotrophic Lateral Sclerosis

Dr Geoffrey Tranmer

TST-34 KCC2 as a novel biomarker and therapeutic target for motoneuron degenerative disease

Dr Sahara Khademullah

TST-35 Unveiling the Neuroprotective Effect of Lactocaseibacillus rhamnosus HA-114 on ALS Progression and Lipid Profiles in mice

Miss Audrey Labarre

TST-36 Optimising sub-threshold transcranial magnetic stimulation as a therapy for ALS

Professor Catherine Blizzard

TST-37 The Use of Remote Ischemic Conditioning for the Treatment of ALS

Mr Mankarman Ghuman

THEME 08

Clinical Imaging and Electrophysiology

IMG-01 Longitudinal spinal cord MRI Study Reveals Potential Neurodevelopmental Disorder in C9orf72 Mutation Carriers

Dr Giorgia Querin

IMG-02 Application of 7 tesla susceptibility weighted MRI in the clinical evaluation of suspected ALS

Dr Jaimin Shah

IMG-03 Laminar fMRI in the locked-in stage of amyotrophic lateral sclerosis shows preserved activity in layer Vb of primary motor cortex

Lasse Knudsen

IMG-04 Characteristics of the threshold tracking TMS and 18F-THK5351 PET for the detection of ALS lesions in the primary motor cortex

Dr Mana Higashihara

IMG-05 Electroencephalography (EEG) during Transcranial Magnetic Stimulation (TMS) reveals a distinguishing marker of early ALS

Miss Anna Carobin

IMG-06 In search of biomarkers in Amyotrophic Lateral Sclerosis

Dr Barbara Aymee Hernandez

IMG-07 Resting-state beta-band EEG alterations in asymptomatic C9orf72 repeat expansion carriers

Dr Stefan Dukic

IMG-08 EEG activation patterns during a motor task in ALS

Dr Stefan Dukic

IMG-09 Electromyographic tools to estimate the number of functional motor units in upper and lower limb muscles of patients with ALS

Dr Salvador Martínez

IMG-10 The role of the upper motor neuron in the generation of fasciculations in early disease stages of ALS

Dr Miguel Oliveira Santos

IMG-11 Amyotrophic Lateral Sclerosis associated with Sensory Neuronopathy

MD Miguel Oliveira Santos

IMG-12 The number of muscles with ultrasonography-detected fasciculations correlates with the progression rate of ALS

Dr Kota Bokuda

IMG-13 The relationship between cardiac autonomic function and cognition in ALS may be related to the corresponding nerve fiber bundles

Ms Zehui Li

IMG-14 Threshold fluctuations in single human motor axons: insights from low- and high-threshold motor units in patients with ALS and healthy controls

Miss Isabelle Busman

IMG-15 A Case for Sodium-Mediated Excitotoxicity: Increased Sodium Currents and Motoneuron Hyperexcitability in ALS

Dr Monica Gorassini

IMG-16 Quantitative Evaluation of Factors Influencing the 3Hz RNS Test in Patients with ALS

Miss Jinghong Zhang

IMG-17 Development of an exploratory electrophysiology endpoint for use in clinical development in amyotrophic lateral sclerosis

Ms Emma Bowden

IMG-18 Altered Cortical Beta Band Modulation in ALS During Active and Passive Movement

Dr Tobias Sevelsted Stærnøse

IMG-19 Motor cortical beta bursting disruption underpins loss of corticomuscular coherence in ALS

Dr Michael Trubshaw

IMG-20 Motor Neurochemistry Explains Significant Clinical Variance in Amyotrophic Lateral Sclerosis

Mrs Aakanksha Singh

IMG-21 Detection of Corticospinal Tract Degeneration in Amyotrophic Lateral Sclerosis at the Individual Level

Mr Matthew Harrison

IMG-22 Brainstem as a proxy for respiratory and bulbar function in amyotrophic lateral sclerosis

Dr. M Khamaysa

IMG-23 Thoracic Electric Impedance Tomography Detects Lung Volume Changes in Amyotrophic Lateral Sclerosis

Dr Ryan Verity

IMG-24 Computer Tomography based Skeletal Muscle Index can differentiate Spinal bulbar muscular atrophy from Amyotrophic lateral sclerosis: a retrospective study

Professor Jin-Sung Park

IMG-25 Investigating individual survival outcomes in ALS patients using machine learning and Deformation-Based Morphometry

Dr Isabelle Lajoie

THEME 09

Clinical Trials and Trial Design

CLT-01 Evidence of environmental copper exposure as a risk factor for ALS

Dr Geneviève Matte

CLT-02 Clinical Development of LTX-002, an ASO for the treatment for ALS

Dr Lawrence Severt

CLT-03 Polysomnographic titration of non-invasive ventilation in motor neurone disease (3TLA): Study protocol for a randomised controlled trial

Dr David Berlowitz

CLT-04 Polysomnographic titration of non-invasive ventilation in motor neurone disease (3TLA): Protocol for a process evaluation of a clinical trial

Dr David Berlowitz

CLT-05 Baseline and safety data from IASO, a pioneering open-label phase 1b pilot trial assessing the safety, tolerability and gut microbiota Analysis of an Oral microbiotherapy in ALS

Dr Adele Hesters

CLT-06 EPISOD1: A Phase 1/2, Multicenter Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Patients with SOD1 ALS (SOD1-ALS)

Dr Brenda Vincenzi

CLT-07 First-in-human study design to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of ALN-SOD in patients with amyotrophic lateral sclerosis and SOD1 variants

Dr Oren Levy

CLT-08 Trial of Oxaloacetate in ALS, TOALS

Dr. Omar Jawdat

CLT-09 A Phase 1, Multicenter, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in ALS (LUMINA)

Dr Lauren Kett

CLT-10 PRO-101: Study design and interim results from a hybrid Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of prosetin in ALS

Ms Erin Fleming

CLT-11 ANQUR - A study evaluating safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Dr Angela Genge

CLT-12 QRL-101-01 – a single, ascending dose study evaluating safety of a KCNQ2/3 modulator in healthy volunteers & next steps for development in ALS

Dr Angela Genge

CLT-13 Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Patients with Amyotrophic Lateral Sclerosis: A Phase 2a Study in Progress

Dr Roeland Vanhauwaert

CLT-14 NX210c for recovering Blood Brain Barrier integrity in ALS patients: in silico modelling complements statistical analysis of fluid biomarkers for dose selection and design of a phase II study

Dr Annette Janus

CLT-15 Targeting cortical excitability with novel transcranial magnetic stimulation paradigms in ALS: a biomarker-directed clinical trial

Dr Agessandro Abrahao

CLT-16 A phase 2a study of TPN-101, a nucleoside reverse transcriptase inhibitor, in patients with c9orf72-related ALS/FTD

Dr Andrew Satlin

CLT-17 Clinical trial of bosutinib for amyotrophic lateral sclerosis: Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic Lateral Sclerosis Medicine (iDReAM) study

Professor Haruhisa Inoue

CLT-18 COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibutilast) in ALS: Trial Update and Interim Analysis Results

Dr Björn Oskarsson

CLT-19 CardinALS: a phase 2, randomized, double-blind, placebo-controlled study of utreloxastat (PTC857) in patients with ALS

Dr Aaron Tansy

CLT-20 Issues for the further development of ambroxol in ALS/MND

Professor Michael Spedding

CLT-21 Shifting the PARADIGM: PrimeC, an Oral Candidate For Amyotrophic Lateral Sclerosis (ALS), Demonstrates Target Engagement Biomarkers in a 12-Month, Phase 2b Trial

Dr. Christian Lunetta

CLT-22 A study to evaluate the efficacy and safety of VHB937 in participants with ALS: The ASTRALS double-blind, randomized, placebo-controlled study

Dr Ram Miller

CLT-23 Systemic Innate Immune System Restoration with NP001 as a Therapeutic Approach for ALS: Long Term Survival Extended in Patients Showing Evidence for Innate Immune Dysfunction

Dr Matthew Davis

CLT-24 Pridopidine For the Treatment of ALS – Significant Improvements in Definite, Probable, and Early (<18mo from onset) Subjects in the Phase 2 Healey ALS Platform Trial

Dr Randal Hand

CLT-25 Statistical Innovation and Complexities in the HEALEY ALS Platform Trial: Lessons Learned From the First Set of Regimens

Dr Melanie Quintana

CLT-26 Endpoint Selection for Improved ALS Clinical Trial Efficiency: Lessons from the HEALEY ALS Platform Trial

Dr. Sabrina Paganoni

CLT-27 Evidence for Long-term Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations

Mr Michael Hotchkin

CLT-28 RESTORE-ALS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial in Early Symptomatic Participants on Stable Background Therapy to Reduce Mortality and Clinical Worsening Morbidity Events in Amyotrophic Lateral Sclerosis

Dr Marjan Sepassi

CLT-29 Phase 3b Study MT-1186-A04 Extension Study to Evaluate the Continued Efficacy and Safety of Radicava ORS® (Oral Edaravone) for up to an Additional 48-Weeks in Patients With Amyotrophic Lateral Sclerosis

Dr Stephen Apple

CLT-30 Phase 3b Study MT-1186-A02 to Investigate the Superiority of Daily Dosing vs the FDA-approved On/Off Regimen of Oral Edaravone (Radicava ORS®) in Patients with ALS

Alejandro Salah

CLT-31 Phase 3, Open-Label, Safety Extension Study of Oral Edaravone (Radicava ORS®) Administered Over 96 Weeks in Patients with ALS (MT-1186-A03)

Alejandro Salah

CLT-32 Post-hoc analysis of the ADORE study: an international, phase 3 trial to investigate the efficacy and safety of daily oral edaravone (FNP122) in ALS

Dr Ruben van Eijk

CLT-33 Innovative Trial Designs for ALS: Are Time-to-Event Endpoints worthwhile?

Dr Ruben van Eijk

CLT-34 Harnessing e-learning for ALS clinical trials - TRICALS Academy's online training platform elevated with an electrophysiological module

Mr Boudewijn T.H.M. Sleutjes

CLT-35 Perspectives on clinical development in amyotrophic lateral sclerosis – Learnings and impact from one year of QurAlis' Global Patient Advisory Council

Ms Emma Bowden

CLT-36 EXPERTS-ALS: What can we learn from patient experiences?

Dr Alys Wyn Griffiths

CLT-37 Breaking down barriers: exploring the involvement of people with lived experience in MND research in Australia

Professor Catherine Blizzard

CLT-38 Lessons from the First Half: A Mid-Course Assessment of the ACT for ALS

Professor Ken Menkhaus

CLT-39 Pharmaceutical Landscape in ALS: industry perspective

Mrs Famke Cosijn

CLT-40 An international, longitudinal exploration of the EQ-5D-5L in Amyotrophic Lateral Sclerosis

Dr Robert McFarlane

CLT-41 Reliability and consistency of the Japanese version of the Primary Lateral Sclerosis Functional Rating Scale (PLSFRS)

Professor Osamu Kano

CLT-42 Canadian regulatory framework and flexibility in the context of rare diseases with unmet medical need such as amyotrophic lateral sclerosis (ALS)

Dr Amelie Vezina

CLT-43 The Northeast ALS Consortium: Advancing ALS Research through Collaboration and Innovation

Ms. Carly Allen

CLT-44 A systematic review exploring remote monitoring of physical behaviour in people living with motor neuron disease: Current findings and implications for clinical trials

Ms Nina Mitic

CLT-45 A systematic review exploring remote monitoring of physical behaviour in motor neuron disease: capabilities and practicalities of current devices

Dr Esther Hobson

CLT-46 Participant expectations and experiences of consumer- and research-grade wearable sensors in ALS research

Dr Gordon Jewett

CLT-47 Customer Experience in ALS Clinical Trial Inquiry in North America - A Project Revisited

Ms M. C. Collet

CLT-48 CAPTURE ALS: Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS

Miss Natalie Saunders

CLT-49 Opportunities to reduce patient burden in clinical trials for people living with ALS

Ms Rosemarie Sellati

CLT-50 An innovative online research platform for participant recruitment, engagement, and data collection

Dr Liam Knox

CLT-51 Les Turner ALS Foundation & NEALS' Collaborative Development of Tools for Increasing Participation in ALS Clinical Research

Ms Lauren Webb

CLT-52 An open-label phase 2a study to assess the safety and tolerability of Trimetazidine in patients with amyotrophic lateral sclerosis

Prof Frederik Steyn

THEME 10

Disease Stratification and Phenotyping of Patients

DSP-01 POSTER WITHDRAWN

DSP-02 PRECISION ALS: A Large-Scale pan-European Approach at Understanding and Targeting the Heterogeneity of Amyotrophic Lateral Sclerosis

Mr Éanna Mac Domhnaill

DSP-03 Evolution of the treatment landscape for patients diagnosed with ALS in the United States

Ms Malgorzata Ciepielewska

DSP-04 Preliminary Analysis of Treatment Combinations in Patients With Amyotrophic Lateral Sclerosis Enrolled in an US-Based Administrative Claims Database

Ms Malgorzata Ciepielewska

DSP-05 ALSFRS-R Subscore progression is phenotype specific and stable through disease accumulation in ALS patients

Isabelle Buchholz

DSP-06 Multi-muscle CMAP-SCANS in clinical trials

Mr Diederik Stikvoort Garcia

DSP-07 Primary lateral sclerosis (PLS) cognitive/behavioral function: does it differ from that of predominant upper motor neuron ALS (PUMN-ALS) at time of diagnosis?

Professor Adriano Chio

DSP-08 Investigating pure lower motor neuron phenotypes at King's: our 10-year experience

Dr James Bashford

DSP-09 Bi-allelic ATXN2 repeat expansions cause autosomal, recessive ALS with slow progression and lower limb onset

Dr. Michael van Es

DSP-10 Distinct patterns of CNS damage along the spectrum of atxn2-related disorders

Mr Paulo Wolmer

DSP-11 Identification of proteomic clusters in the CSF of sporadic ALS patients

Dr Laura Tzeplaeff

DSP-12 Phenotype and prognosis of patients with sporadic ALS in the Japanese ALS registry

Dr Naoki Atsuta

DSP-13 CXCL12, a potential biomarker for differential diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Dr Mónica Povedano-Panades

DSP-14 Prospective natural history study of ALS clinical characteristics and body fluid biomarkers in Taiwan

Dr Kang-yang Jih

DSP-15 Identification of molecular subtypes of ALS in whole blood and induced pluripotent stem cell motor neuron models using traditional and novel data representation approaches

Dr Mariah Hoffman

DSP-16 Differences in Autonomic Nervous Regulation across Phenotypes and Stages of ALS: Analysis of Heart Rate Variability Responses to Task Load

Ms Juri Sawada

DSP-17 Distinct inflammatory signatures associated with astrocyte TDP-43 burden in C9orf72 and sporadic ALS

Miss Orjona Stella Taso

DSP-18 Dates of Onset and Diagnosis as Indicators and Predictors of Data Quality in Clinical Research

Mr Alexander Sherman

DSP-19 Cross-sectional study of 141 East African patients with amyotrophic lateral sclerosis presenting to a tertiary neurology centre in Kenya

Dr Dilraj Sokhi

DSP-20 Identifying People with Amyotrophic Lateral Sclerosis through an Automatic Dysarthria Score Across Multiple Languages

Dr Tabea Thies

DSP-21 Towards interpretable measures of impairment in ALS speech assessment

Dr Leif Simmatis

DSP-22 Smartphone capture of biomarkers for speech and swallowing in ALS

Dr Andrew Geronimo

DSP-23 Linguistic Features of Automatically Transcribed Speech from ALS Patients

David Suendermann-Oeft

DSP-24 Towards improving clinical trial design and participant stratification in ALS with digital speech biomarkers

David Suendermann-Oeft

DSP-25 Smartphone Application-Mediated, Supervised, At-Home Telespirometry Vital Capacity Measurements in Amyotrophic Lateral Sclerosis: Comparison of American Thoracic Society/European Respiratory Society Point-of-Care Quality Assessment Algorithms Implemented for Slow Vital Capacity and Forced Vital Capacity (NCT05106569)

Dr Eufrosina Young

DSP-26 Smartphone Application-Mediated Supervised At-Home Telespirometry Erect and Supine Slow Vital Capacity (eSVC/sSVC) Measurements in Subjects With Amyotrophic Lateral Sclerosis Identify Statistically Significant Differences in eSVC/sSVC Decline as Function of Non-Invasive Ventilation Treatment Status (NCT05106569)

Dr Eufrosina Young

DSP-27 Respiratory Phenotypes in ALS: Their Impact on Disease Progression and Mortality

Dr Muhannad Seyam

DSP-28 Assessing respiratory failure in ALS: a consensus clustering approach

Dr Umberto Manera

DSP-29 Clinical validation of segmental acoustic measures of velopharyngeal dysfunction (VPD) in ALS

Ms Chelsea Tanchip

DSP-30 The role of gastrostomy and noninvasive ventilation in primary lateral sclerosis

Dr Miguel Oliveira Santos

DSP-31 UNC13A polymorphism is associated with shorter survival in frontotemporal dementia

Mr Sean Willemse

THEME 11

Cognitive and Psychological Assessment and Support

COG-01 Psychosocial adjustment in Amyotrophic Lateral Sclerosis and Huntington's Disease: a comparative analysis

Professor Dorothée E. Lulé

COG-02 Enhanced memory performance and reduced social skills provides evidence for alternative cognitive profile in C9orf72 HRE mutation carriers

Professor Dorothée Lulé

COG-03 An online support intervention targeting adult children of PALS who no longer live at home

Dr Lene Klem Olesen

COG-04 Laptop-based Testing of Emotion Discrimination and Interoception in ALS

Miss Camilla Hakala

COG-05 Does carer anxiety and depression moderate the relationship between MND behavioural symptoms and carer anticipatory grief emotions?

Dr Ana Paula Trucco

COG-06 iDeliver MND: improving delivery of psychological care in MND through discussions with health care professionals

Dr Emily Mayberry

COG-07 Digitized Cognitive Assessment for ALS Patients: Implementation and Predictive Analysis Using Speech Samples and correlations with other ALS metrics and Kings stage

Ms Indu Navar Bingham

COG-08 Longitudinal cognitive assessment using the Cumulus home-based EEG platform in ALS and FTD

Dr Emmet Costello

COG-09 Trajectory of the cognitive profile in ALS: results from a longitudinal monocentric study

Dr Luca Diamanti

COG-10 Longitudinal cluster analysis of apathy profiles in a Swedish ALS cohort

Mrs Juliette Foucher

COG-11 Sex-specific cognitive differences in ALS

Dr Maurizio Grassano

COG-12 A Novel Exploration of Sexual behavior and Intimacy in ALS

Dr. Mansoureh Mamarabadi

THEME 12

Clinical Management and Support

CMS-01 Digital Gait Measures by Three-Dimensional (3D) Motion Capture for Monitoring Disease Progression in ALS

Ms Akiko Goto

CMS-02 POSTER WITHDRAWN

CMS-03 Description of the dysarthria in Spinal and Bulbar Muscular Atrophy

Dr Nathalie Leveque

CMS-04 Assessment of speech and swallow in MND and potential of remote monitoring: an international survey of speech and language therapists

Miss Lesley Doyle

CMS-05 Feeding Tube Placement in ALS Patients with Suboptimal Respiratory Status

Mrs Rachel Meaney

CMS-06 Prevalence of dysphagia-related symptoms in ALS, and their effect on swallowing-related quality of life and dysphagia severity

Dr Camilla Cattaneo

CMS-07 Voice assessment in patients with amyotrophic lateral sclerosis and its relationship to bulbar and respiratory function

Dr Pedro Santos-Rocha

CMS-08 HomeSenseALS: A Mobile App to Enhance Remote Monitoring and Disease Management in ALS

Dr Pedro Santos-Rocha

CMS-09 Effect of regular lung volume recruitment in people living with amyotrophic lateral sclerosis: post-hoc analysis of a randomised controlled trial

Dr Nicole Sheers

CMS-10 A scoping review of upper airway disorders in ALS and motor neuron disease patients

M Carl Larocque

CMS-11 Delivering Effective Non-Invasive ventilation in Motor neuron disease using intensive, remote optimisation (DENIM): a protocol for a type III hybrid implementation-effectiveness cluster stepped wedge randomised controlled trial

Dr Esther Hobson

CMS-12 Understanding the uptake of non-invasive ventilation in MND: results of a national survey

Dr Marnie Graco

CMS-13 Understanding the key influences on uptake of non-invasive ventilation from the perspective of people living with motor neurone disease and their carers: a qualitative study using the COM-B model of behaviour

Dr Marnie Graco

CMS-14 POSTER WITHDRAWN

CMS-15 Survival Time on Tracheostomy-Invasive Ventilation (TIV) unchanged in Two Community-Based Longitudinal Observational Studies with Increased Survival Time When NIV Prescribed Before TIV

Mrs Pamela Cazzolli

CMS-16 Decision-making about gastrostomy placement and ventilation in motor neuron disease care: a qualitative evidence synthesis

Mr Sean White

CMS-17 Mortality and complications after percutaneous gastrostomy in amyotrophic lateral sclerosis patients: a retrospective study

Dr Jean-Simon Dallaire

CMS-18 Palliative care in patients with ALS: population-based study from 2016 to 2024

Professor Andrea Calvo

CMS-19 Real-world evidence of Riluzole on Survival and ALSFRS Change in a Chinese ALS Cohort

Professor Min Deng

CMS-20 Interaction between riluzole treatment and dietary glycemic index in the disease progression of amyotrophic lateral sclerosis

Dr Ikjae Lee

CMS-21 ASO associated myelitis successfully treated with intrathecal hydrocortisone

Dr Gary Pattee

CMS-22 Tetrahydrocannabinol/Cannabidiol (THC:CBD) in the symptomatic treatment of patients with ALS – data analysis from a multicenter registry study

Dr Susanne Spittel

CMS-23 The existing profile among the Motor Neurone Disease (MND) patients and the role of supplements in MND

Mrs Justyna Reinert

CMS-24 Current rehabilitation approaches in ALS/MND and use of technology; an international survey of physiotherapists and occupational therapists

Ms Avril Mc Tague

CMS-25 Evaluation of a remote monitoring and communication system (TiM) used in a specialist multidisciplinary MND clinic: a qualitative study of user experiences

Mr David Murphy

CMS-26 Assessment of manual function in amyotrophic lateral sclerosis (ALS) with the ALS pen – prototyping of the device and conduction of a feasibility study

Dr André Maier

CMS-27 Head-to-head comparison between the harmonized and the self-explanatory version of the ALS functional rating scale: results of a prospective study

Dr André Maier

CMS-28 Validation of the Somatic Symptoms Scale (SSS-8) in Patients with Amyotrophic Lateral Sclerosis

Dr Andrea Lizio

CMS-29 Reliability study for the Japanese version of the Columbia Muscle Cramp Scale in amyotrophic lateral sclerosis

Mr Masahiro Sawada

CMS-30 The ALSMOND population based registry for Neuromuscular and Motoneuron diseases in Northwest Germany: the Hanse experience

Mrs Isabelle Buchholz

CMS-31 Prognostic communication in Amyotrophic Lateral Sclerosis: Findings from an Italian Survey

Professor Cristina Moglia

CMS-32 Venous Thromboembolism in Motor Neurone Disease: A Retrospective Study

Dr Andrew W Barritt

CMS-33 Clinical, neurofilament light-chain response and patient-reported outcomes to tofersen in SOD1-ALS: Results of a multicenter observational study over 18 months

Mrs Peggy Schumann

CMS-34 Age and life stage in the experience of ALS: a scoping review

Dr Andrea Parks

CMS-35 Time to intervention events in ALS: A real-world cohort analysis

Dr Senthil Kumar Subramanian

CMS-36 Sexual Health and Intimacy in Patients with ALS/MND: Improving the Discussion in Clinical Practice

Mrs Cassie Kuhn

CMS-37 Nutritional care practice in ALS: perspectives from patients and healthcare professionals

Dr Anita Beelen

CMS-38 Effect of Caloric Balance on Disease Progression and Survival in ALS

Miss Rachel Thompson

CMS-39 A retrospective comparative study of MND care and research participation in Scotland from 2015-2023 based on the NICE guidelines (2016)

Mr Isaac Chau

CMS-40 The establishment of the Italian ALS Coalition: Outline of the policy changes needed across Italy to improve the lives of People Living with ALS (PLWALS) and their caregivers

Mr Silverio Conte

CMS-41 'An unimaginable challenge': A cross-cultural qualitative study of ethics and decision-making around tracheostomy ventilation in patients with Amyotrophic Lateral Sclerosis

Dr Reina Ozeki-Hayashi

CMS-42 Navigating complex data governance issues in cross-national, cross-sectoral, multidisciplinary real world health research

Dr Miriam Galvin

CMS-43 Informal caregiving in ALS: a gendered analysis

Dr Miriam Galvin

CMS-44 Advance care planning and health communication: Experiences of Canadians with Amyotrophic Lateral Sclerosis (ALS) and family caregivers

Dr Shelagh K Genuis

CMS-45 Understanding the care of people living with Motor Neurone Disease during the COVID-19 pandemic: a concurrent mixed method study

Mrs Helen Aret Brewah

CMS-46 On the Validation of Tidal/End-Tidal CO₂ in ALS (VOTECO2ALS) using novel high resolution point-of-care capnometry

Dr John Altrip

CMS-47 Chatbots and the information needs of people with amyotrophic lateral sclerosis and their caregivers: a scoping review

Miss Julie Desgroseilliers

CMS-48 The Association of Communication Impairment and Loneliness of People Living with ALS

Dr Katherine Burke

CMS-49 Virtual Reality Guided Breathing Exercise for Anxiety Management in Amyotrophic Lateral Sclerosis

Mr Shane McCullum

CMS-50 Healthcare students' skills and perceived burden were shown to improve after 6 months of a single AAC education programme with e-learning

Mr Takemasa Ishikawa

CMS-51 Health Related Quality of Life of the Dutch population of people living with MND evaluated with the PROMIS-10 Global Health

Mrs Ann Katrin Schmidt

CMS-52 An emerging era in Italy: The impact of the PALS-led volunteers from Associazione conSLAncio Onlus

Dr Silvia Pozzi

CMS-53 A review of veteran participation in clinical trials: questions and solutions

Mrs Mandi Bailey

CMS-54 POSTER WITHDRAWN

CMS-55 Patients Perspective on the Financial Burden of ALS in the Republic of Kazakhstan and a Call for Change

Professor Kuanova Larissa

CMS-56 A Qualitative Study Exploring Healthcare Professionals Experiences of Working with Motor Neurone Disease (MND) in Irish Healthcare Services

Ms Megan Walls

CMS-57 Exploration of factors impacting sustained clinical care by multidisciplinary professionals for amyotrophic lateral sclerosis

Shouko Serizawa

CMS-58 Experiences with Comorbid Frontotemporal Degeneration and Amyotrophic Lateral Sclerosis

Dr Shana Dodge

CMS-59 Exploring the experience of individuals living with MND that do not have a gastrostomy placed and the factors that influence this decision

Miss Michaela Waltho

Biomedical Work in Progress

BW-01 Characterizing microbial markers predictive for ALS onset and Progression

Dr Catherine Lomen-hoerth

BW-02 Identifying and validating molecular subtypes of ALS as biomarkers of onset and progression

Dr Heather Marriott

BW-03 Identifying targetable motor neuron disease pathways associated with metal toxicities and imbalances in ALS patients

Mr Kevin Cornell

BW-04 California's Risky Air Pollution: A Systematic Survey of Mean Annual Outdoor PM_{2.5} Exposure for UCSF ALS Patients

Mr Zane Ashkar

BW-05 A role for lipidation in ALS and MSP

Dr Firyal Ramzan

BW-06 Investigating stress granule dynamics in TDP-43 mutant iPSC-derived microglial-neuron co-cultures

Miss Dulcie Keeley

BW-07 Genotype-Phenotype Analysis in ALS/FTD with TARDBP gene mutations

Miss Dulcie Keeley

BW-08 Applying iterative indirect immunofluorescence imaging (4i) to elucidate the molecular predictors of domain-specific cognitive impairment in ALS-FTD

Mr Luke Reilly

BW-09 Combinatorial Analysis of ALS Patients Uncovers New Disease Drivers in Genetically Defined Subgroups

Dr Andy Malinowski

BW-10 A Deleterious Intronic Variation Causes Exon 27 Skipping in KIF5A and is Associated with Amyotrophic Lateral Sclerosis

Ms Ziqi Yu

BW-11 Identification of Non-Coding RNA Biomarkers for Disease Prognosis and Progression in ALS

Dr Eleni Christoforidou

BW-12 Investigating motor and amygdala circuitry vulnerability and degeneration in the TDP-43Q331k mouse model of ALS

Miss Lyzette Matthews

BW-13 TDP-43, transcriptomics and taurine: uncovering the consequences of TDP-43 misregulation using single-cell and spatial transcriptomics

Mr Leon Crowley

BW-14 Investigating the Role of TDP-43 in DNA Replication

Dr Sahana Gopalakrishna

BW-15 Investigating Pathologies of TDP43 Mislocalization Using In Vitro Neuromuscular Junction Models

Ms Yiyun Zhang

BW-16 Mapping TDP-43 pathology in ALS patients postmortem tissue

Miss Zoe Butti

BW-17 Characterizing the role of a novel posttranslational modification in TDP-43 mislocalization and ALS pathogenesis

Miss Cailyn Perry

BW-18 Correlating biophysical properties of TDP-43 aggregates with clinical phenotypes in amyotrophic lateral sclerosis

Miss Maddison Charlton

BW-19 Mechanisms of TDP-43 Clearance by Microglia and Implications for Microglial Activation in ALS

Dr Shiden Solomon

BW-20 The role of T cells in amyotrophic lateral sclerosis

Mrs Kristine Roberts

BW-21 Acquired Oculomotor Apraxia in C9orf72-related Familial Primary Lateral Sclerosis

Mr Nathan Hostetler

BW-22 Development of an iPSC-derived neuronal screening platform for MND drug discovery

Dr Erin Hedges

BW-23 Exploring palmitoylation as a potential therapeutic target for ALS and HD

Ms Yasmeen Alshehabi

BW-24 EPIC-ALS: A phase 2 trial of EPI-589 in ALS

Dr Koji Fujita

BW-25 A Phase 2 Study to Assess the Safety, Tolerability, and Pharmacology of 15 mg of Darifenacin Daily in Patients With Amyotrophic Lateral Sclerosis

Dr Oliver Blanchard

BW-26 Modifiers of Early Functional Change with Riluzole Treatment in ALS: Vitamin E (α -tocopherol) and Glycemic Index

Professor Benjamin Rix Brooks

BW-27 Taskforce-led Global Effort: Optimizing ALS/MND Clinical Trial Endpoints

Dr Martina de Majo

BW-28 POSTER WITHDRAWN

BW-29 Developing Multimodal Intelligent Methods for Orofacial and Speech Assessment to predict ALS bulbar decline

Dr Francesca Bianchi

BW-30 The need for an updated definition of FASICS. Observations in a Spanish cohort

Dr Josep Gamez

Care Practice/Work in Progress

CW-01 Kickin' ALS Advocacy Program

Miss Katrina Byrd

CW-02 Distinguishing Motor Unit Population Changes in ALS Through Fatigue-Driven Changes in EMG

Ms Maia Brown

CW-03 Investigating motor cortical network dysfunction in asymptomatic C9orf72 expansion carriers: a threshold tracking TMS study

Dr Narin Suleyman

CW-04 Benefits of Exercise for People Diagnosed with ALS

Mrs Jill Brattain

CW-05 Developing a stimulation-free remote motor unit number estimate in Motor Neurone Disease (REMUNE)

Dr. James Bashford

CW-06 MetALS: A study to investigate the role of metabolic parameters and body composition on disease phenotype and progression in amyotrophic lateral sclerosis (LS)

Miss Theresa Chiwera

CW-07 Defining Information Needed to Determine Monitoring Frequency for People at Genetic Risk of ALS and FTD

Ms Mindy Uhrlaub

CW-08 Case Study on ALS Reversal: An Integrative Medicine Approach to Sporadic Limb-Onset ALS

Dr Martha Herbert

CW-09 Involving people affected by MND in early-stage research: preliminary insights from the LifeArc MND Translational Challenge

Dr Paul Wright

CW-10 Developing a Motor Neuron Disease Massive Open Online Course (MND MOOC) to increase global knowledge, understanding and awareness of MND

Dr Sharn Perry

CW-11 Tim Lowrey ALS Panels: Bringing Lived Experience into Undergraduate and Graduate Health Sciences Classrooms

Mr Tim Abeska

CW-12 Assistive Technology in ALS: A Scoping Review of Devices for Limb, Trunk, and Neck Weakness

Dr Katherine Burke

CW-13 Preliminary Results from the 'Caring for the Homebound Patient with ALS' Pilot Study

Dr Keelie Denson

CW-14 Working Collaboratively to Enhance Patient Experience in the Organ Donation Trajectory after Medical Assistance in Dying (MAiD) among ALS Patients

Ms Lysane Desrosiers

CW-15 The Burden of Delayed ALS Diagnosis: Unnecessary Procedural Intervention & Healthcare Costs

Ms Tali Sorets

CW-16 Quality of life in family caregivers of patients with amyotrophic lateral sclerosis in China

Professor Wen-Jun Cao

CW-17 The experiences of younger middle-aged adults with ALS

Dr Andrea S. E. Parks

CW-18 Online course for people with ALS and their relatives facilitates education, peer-to-peer and professional support

Mrs Signe Versterre

CW-19 Patient profiles and speech-language pathology practice patterns in an annual cohort of people with motor neuron disease from a large multidisciplinary clinic

Ms Julie Stierwalt

CW-20 In Progress: Combined Respiratory Training to Improve Pulmonary and Cough Function in pALS

Dr Lauren Tabor Gray

CW-21 Effect and side effects of dextromethorphan/quinidine for bulbar and pseudobulbar symptoms in motor neuron disease: a Dutch observational cohort study

Mr Sean Willemse

Summary of events

All events will take place on Level 5

Thursday 5 December

09.00 – 12.30	WFN ALS/MND Speciality Group	519a/b
13.30 – 17.00	ENCALS	519a/b
17.00 – 19.00	Project MinE (closed meeting)	519a/b
16.00 – 18.00	Registration International Symposium	517 Foyer
18.00 – 19.30	Welcome Networking Reception	517 Foyer

Friday 6 December

07.00 – 18.00	Registration International Symposium	517 Foyer
07.00 – 18.00	Speaker Room	521a
08.30 – 10.00	Symposium Joint Opening Session	517d
10.00 – 10.30	Refreshments, Networking & Exhibitors	517 Foyer
10.30 – 12.45	Symposium Biomedical Session 2A	520
10.30 – 12.30	Symposium Clinical Session 2B	517d
10.30 – 12.30	Symposium Alternative Session 2C	524
12.30 – 14.00	Lunch and Networking	517a/516
12.45 – 13.45	NEALS (closed meeting)	519a
13.00 – 14.00	PACTALS (closed meeting)	519b
14.00 – 15.30	Symposium Biomedical Session 3A	520
14.00 – 15.30	Symposium Clinical Sessions 3B	517d
14.00 – 15.30	Symposium Alternative Session 3C	524
15.30 – 16.00	Refreshments, Networking & Exhibitors	517 Foyer
16.00 – 17.30	Symposium Biomedical Session 4A	520
16.00 – 17.30	Symposium Clinical Session 4B	517d
16.00 – 17.30	Symposium Alternative Session 4C	524
17.30 – 19.00	Poster Session A	517b/c

Saturday 7 December


07.00 – 18.00	Registration International Symposium	517 Foyer
07.00 – 18.00	Speaker Room	521a
07.00 – 08.30	Industry Sponsored Breakfast Session (Non-CME)	518
08.30 – 10.00	Symposium Biomedical Session 5A	520
08.30 – 10.00	Symposium Clinical Session 5B	517d
08.30 – 10.00	Symposium Alternative Session 5C	524
10.00 – 10.30	Refreshments, Networking & Exhibitors	517 Foyer
10.30 – 12.30	Symposium Biomedical Session 6A	520
10.30 – 12.30	Symposium Clinical Session 6B	517d
10.30 – 12.30	Symposium Alternative Session 6C	524
12.30 – 14.00	Lunch and Networking	517a/516
14.00 – 15.30	Symposium Biomedical Session 7A	520
14.00 – 15.30	Symposium Clinical Session 7B	517d
14.00 – 15.30	Symposium Alternative Session 7C	524
15.30 – 16.00	Refreshments, Networking & Exhibitors	517 Foyer
16.00 – 17.30	Symposium Biomedical Session 8A	520
16.00 – 17.30	Symposium Clinical Session 8B	517d
16.00 – 17.30	Symposium Alternative Session 8C	524
17.30 – 19.00	Poster Session B	517b/c

Sunday 8 December

08.00 – 12.30	Registration International Symposium	517 Foyer
07.30 – 14.00	Speaker Room	521a
08.30 – 10.00	Poster Session C	517b/c
10.00 – 10.30	Refreshments, Networking & Exhibitors	517 Foyer
10.30 – 12.30	Symposium Clinical Sessions 9A	520
10.30 – 12.30	Symposium Biomedical Session 9B	517d
10.30 – 12.30	Symposium Alternative Session 9C	524
12.30 – 13.30	Lunch and Networking	517a/516
13.30 – 15.20	Symposium Joint Closing Session	517d

Floorplan

Palais des Congres de Montreal



2024 Exhibitors

Please visit our exhibitors, located online and in the 517 Foyer

More information can be found on our website
www.symposium.mndassociation.org, and on the Symposium App



INTERNATIONAL ALLIANCE
OF ALS/MND ASSOCIATIONS



Mitsubishi Tanabe Pharma
America

ONLINE ONLY



Mitsubishi Tanabe Pharma
Canada

ONLINE ONLY



2024 Sponsors

With grateful thanks to the following supporters of the
35th International Symposium on ALS/MND

HEADLINE SPONSOR



Mitsubishi Tanabe Pharma
America



Mitsubishi Tanabe Pharma
Canada

KEY SPONSOR



GENERAL SPONSORS



SAN DIEGO 2025



Join us in San Diego, California
5 - 7 December 2025

Provisional abstract submission deadline:
Thursday 10 July 2025

Stay connected:



@mndresearch
#alsmndsymp

For further information please contact:

Motor Neurone Disease Association

Telephone: +44 (0) 1604 611837

Email: symposium@mndassociation.org

Email: abstracts@mndassociation.org

www.mndassociation.org

www.symposium.mndassociation.org